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ABSTRACT 
Carbohydrate Derivatives in Antibiotics Research 
by 
Yi Liang, Master of Science 
Utah State University, 2009 
 
Major Professor: Dr. Tom Chang  
Department: Chemistry 
 
In this study, we investigated the potential applications of carbohydrates in the 
development of new antibiotics. To tackle the problem of multidrug-resistant variants 
of M. tuberculosis (MDR-TB), we investigated the biosynthesis pathways of trehalose, 
which has contributed to significant drug resistance. Some new methods were 
developed for the synthesis of potential inhibitors (6-azido-trehalose and 
6,6’-diazido-trehalose) that have been designed to imitate the intermediate molecule 
(trehalose 6-phosphate, TPP) of OtsA-OtsB pathway. At the same time, some new 
antibacterial agents based on trehalose have been synthesized.   
Members of the 1,2,3-triazole family have shown interesting biological properties. 
Steroid derivatives have been developed in antibiotics area. Therefore click reaction 
was utilized to build a 1,2,3-triazole ring and combine cholesterol with different 
carbohydrate moieties. A series of new compounds has been synthesized and their 
bioactivities have been tested.                               (122 pages) 
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CHAPTER 1 
INTRODUCTION 
One of the successful themes in human therapeutics from the 20th century was the 
development of antibiotics and antibacterial agents for the treatment of bacterial 
infections. Antibiotics helped drop the death rate from infectious disease from 797 per 
hundred thousand in 1900 to 36 per hundred thousand in 1980.1 Two basic routes of 
chemical investigation were proved as well-suited in antibiotics research: the isolation 
from natural products with antibiotic activities and the synthesis of antibacterial agents. 
Table 1 shows the first route is most common. 
1. Resistance for antibiotics 
In the 1950s, when antibiotics were first introduced for the treatment of microbial 
infection, the bacterial geneticists believed by mistake that the development of 
antibiotic resistance during therapy was unlikely. For instance, most early research of 
antibiotic resistance involved lab experiments with Enterobacteriaceae such as 
Escherichia coli or Salmonella typhimurium. For these procaryotes a mutation 
frequency of 10-9 or less per bacterial generation was found. Hence at that time, the 
development of antibiotic-resistant strains was not supposed to be a serious problem. 
However, today a wide variety of resistance mechanisms have been known. For 
example, genes encoding resistance to antibiotics would be carried by autonomously 
replicating transferable elements. Table 2 identifies some mechanisms. 
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Table 1. History of antibiotic classes in clinical use 
 
Year Antibiotic Class Nature 
product 
Synthetic
1929 (activity) 
1940 (purification) 
1932 
1944 
1945 
1947 
1948 
1950 
1955 
1955 
1955 
1955 
1959 
1962 
1969 
2000 
2003 
penicillin 
 
sufapyridine 
streptomycin 
cephalosporin 
chloramphenicol
chlortetracycline
erythromycin 
vancomycin 
virginiamycin 
amphotericin 
lincomycin 
rifamycin 
nalidixic acid 
fosfomycin 
linezolid 
daptomycin 
β-lactam 
 
sulfonamide 
aminoglycoside 
β-lactam 
phenypropanoid 
tetracycline 
macrolide 
glycopeptides 
streptogramin 
polyene(antifungal)
lincosamide 
ansamycin 
quinolone 
phosphonate 
oxazolidinone 
lipopeptide 
√ 
 
 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
 
√ 
 
√ 
 
 
√ 
 
 
 
 
 
 
 
 
 
 
√ 
 
√ 
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Table 2. Transferable antibiotic resistance in bacteria. For the thorough overview of 
biochemical mechanisms of drug resistance, see Hayes and Wolf 3 
 
Mechanism Antibiotics 
Reduced uptake into cell  
Active efflux from cell 
Modification of target to eliminate or reduce 
binding of antibiotic 
Inactivation of antibiotic by enzyme modification
Hydrolysis 
 
Derivatization  
 
 
Sequestration of antibiotic by protein binding  
Metabolic bypass of inhibited reaction  
 
Binding of specific immunity protein to antibiotic
Overproduction of antibiotic target 
Chloamphenicol 
Tetracycline 
β-lactams 
Erythromycin 
Lincomycin 
β-lactams 
Erythromycin 
Aminoglycosides 
Chloamphenicol 
Fosfomycin 
Fusidic acid 
Sulfonamides 
Trimethoprim 
Bleomycin 
Sulfonamide 
Tremethoprim 
 
For those, there are three major mechanisms (Figure 1) of antibiotic resistance 
revealing a few common themes underlying principle about bacterial defense against 
antibiotics: A, the antibiotic is pumped out by the bacteria efflux pump on the cell wall. 
B, the antibiotic’s interaction with the target is weakened through modification by 
bacterial enzymes. C, the antibiotic target is modified in the bacterial genome.4  
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Figure 1. Mechanisms of bacterial drug resistance4 
The emergence of multi-drug-resistant microorganisms leads to stringent public 
health problems.5-9 The annual cost of treating lift-threatening antibiotic resistant 
infections in the United States has been estimated to be as high as $30 billion.10, 11 This 
situation promotes new drug development worldwide. 
To date, even vancomycin, the last resort of antibiotics active against 
Staphylococcus aureus and some other Gram-positive bacteria, has encountered 
resistance,12 and this new public health crisis has renewed the interest in antibacterial 
development.13 
Currently, the common strategies for resolving the problem of antibiotic resistance 
involve chemical modification of existing antibiotics to resist those mechanisms or 
development of new types of antibiotics. Our interest in this area is to develop new 
antibiotics by modification of carbohydrates and their derivatives. 
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2. Carbohydrate in new antibiotics 
2.1 New fields in carbohydrate research 
Although the development of vaccines based on carbohydrates has a long history, 
there are some new emerging fields of interest in the chemistry and biology of 
carbohydrate. Carbohydrate modifications of proteins and lipids are very important 
processes which can modulate the structures and functions of these biomolecules and 
affect intercellular recognition in infection, cancer, and immune response. The most 
recent efforts in this field are to develope new tools for use to understand the 
molecular-level carbohydrate recognition and to enable the carbohydrate-based drug 
discovery process. 
 
Figure 2. The cell walls of bacteria14 
For example, both Gram-positive and Gram-negative bacteria have substantial 
differences in the structures surrounding the cells which form a strong, protective 
peptidoglycan layer (Figure 2). Many Gram-positive bacteria modify their 
peptidoglycan layers with anionic wall teichoic acid (WTA) polymers (Figure 3) via 
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a highly conserved disaccharide bridge. Inhibition of the biosynthesis of this bridge is 
a potential antibiotic strategy. Ideally, compounds that specifically target the 
biosynthesis of these anionic polymers could be developed as new antibiotics. The 
first chemical and enzymatic synthesis of key substrates for the first two committed 
steps in WTA biosynthesis are reported along with characterization of the two 
enzymes, TagA and TagB, which carry out this chemistry. 14  
 
Figure 3. Teichoic acid polymer linked to peptidoglycan14 
Unlike those of Gram-negative bacteria, the peptidoglycan layers of 
Gram-positive bacteria are often modified by teichoic acids. Penicillin inhibits the 
biosynthesis of the peptidoglycan layer of many Gram-positive bacteria and some 
Gram-negative bacteria, but resistance to this and related antibiotics make inhibition 
of alternate biosynthetic targets very attractive. 
TagA and TagB catalyze the biosynthesis of the highly conserved bridge between 
peptidoglycan and teichoic acid polymers. One potential antibiotic strategy that can be 
explored is to inhibit the reactions catalyzed by TagA and TagB. 
  
7
2.2 Carbohydrates as future anti-adhesion  
drugs for infectious diseases 
To effectively colonize a host animal and cause disease, many bacterial pathogens 
have evolved means for attachment or adhesion to the host cells and tissues. Adhesion 
is required so that the organisms are not swept away by the natural cleansing 
mechanisms of the host. The most common means of adhesion, expressed by numerous 
bacteria, are surface lectins that combine with complementary carbohydrates present on 
the host cell surfaces. Blocking or inhibition of these lectins by suitable carbohydrates 
or their analogs for the prevention and treatment of microbial diseases is the aim of 
anti-adhesion therapy of such diseases.15 
From a medical point of view, molecular intervention of this kind may be 
considered mild and gentle, and more sound ecologically, as well as safer, compared 
with present chemotherapy approaches. Saccharides are ideal for this purpose as they 
are unlikely to be toxic or immunogenic. 
Although only a small number of the bacterial surface lectins have been well- 
characterized, the existence of many has been inferred from, and their specificity 
investigated by inhibition experiments, in which the effect of different carbohydrates is 
examined on adhesion of the bacteria to relevant animal cells or on the agglutination by 
the bacteria of erythrocytes16 or other kinds of cell, such as yeasts.17 Until the early 
1980s, bacteria specific for mannose were identified, namely type 1 fimbriated strain E. 
coli. Since then, E. coli strains with diverse specificities were discovered (Table 3). 
(Glc:glucose; Gal:galactose; Fuc:fucose; Man:mannose; NeuAc:N-acetylneuraminic 
acid). 
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Table 3. Carbohydrates as attachment sites for bacterial pathogens on animal tissues. 
aUnless otherwise noted, see Ref. 18. bPredominant form in tissue: GP, glycoproteins; 
GSL, glycolipids. cRef. 19. dRef. 20. eRef. 21. fRef. 22. 
Organism Target 
tissue 
Carbohydrate Formb 
C. jejunic Intestinal Fucα2GalβGlcNAc GP 
E. coli Type 1 Urinary Manα3Manα6Man GP 
P Urinary Galα4Gal GSL 
S Neural NeuAc (α2–3)Galβ3GalNAc GSL 
CFA/1 Intestinal NeuAc (α2–8)– GP 
F1C d Urinary GalNAcβ4Galβ GSL 
F17 e Urinary GlcNAc GP 
K1 Endothelial GlcNAcβ4GlcNAc GP 
K99 Intestinal NeuAc(α2–3)Galβ4Glc GSL 
H. influenzae Respiratory [NeuAc(α2–3)]0,1 
Galβ4GlcNAcβ3Galβ4GlcNAc 
GSL 
H. pylori Stomach NeuAc(α2–3)Galβ4GlcNAc 
Fucα2Galβ3(Fucα4)Gal 
GP 
GP 
K. pneumoniae Respiratory Man GP 
N. gonorrhoea Genital Galβ4Glc(NAc) GSL 
N. meningitidis Respiratory [NeuAc(α2–3)]0,1 
Galβ4GlcNAcβ3Galβ4GlcNAc 
GSL 
P. aeruginosaf Respiratory
Respiratory
L-Fuc 
Galβ3Glc(NAc)β3Galβ4Glc 
GP 
GSL 
S. typhimurium Intestinal Man GP 
S. pneumoniae Respiratory [NeuAc(α2–3)]0,1 
Galβ4GlcNAcβ3Galβ4GlcNAc 
GSL 
S. suis Respiratory Galα4Galβ4Glc GSL 
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The presence of multiple lectins with distinct sugar specificities that are encoded by 
DNA often located on the same chromosome of the pathogen is most likely the major 
impediment for the use of sugars as anti-adhesion drugs. To overcome this problem, it 
is necessary to learn more about the lectins of the bacterial pathogens and the factors 
affecting their expression in the course of natural infection. This will allow the 
preparation of suitable cocktails of inhibitory sugars for the treatment of bacterial 
infections, instead of the single sugars in use until now. The low affinity of free 
saccharides to the bacterial lectins is another stumbling block, which may be overcome 
by their attachment to polymeric carriers or presentation as dendrimers. Production of 
the oligosaccharides is still extremely costly, and to act effectively, large doses are 
required. However, new technologies, in particular the use of engineered bacteria, 23 
promise to lower this cost markedly. Another possibility is to develop suitable 
carbohydrate analogs (glycomimetics) that are more potent inhibitors. 
 
2.3 Vaccines based on the carbohydrates 
 
In recent decades, the gradual increase of the resistance to antibiotics leads to a 
serious threat for treatment of bacterial infection. Establishing the structure of 
carbohydrate immuno-determinants in conjunction with improvements in 
carbohydrate synthesis has rendered it feasible to develop new generations of 
carbohydrate-based vaccines.24 
With a long history from 1923, polysaccharides have been used as vaccines, 
providing immunity. And also the glycoproteins have an even larger immune response 
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for the same antigens. The role of carbohydrate catabolism in the pathogenesis of 
invasive streptococci has been investigated (Figure 4).25 
In Figure 4, proteins involved in deglycosylation of host glycoproteins such as 
NanA, StrH, BgaA and EndoS, StrH and BgaA are cell-surface exoglycosidases 
studied in S. pneumoniae. EndoS is a secreted endoglycosidase studied in group A 
Streptococcus. Pathways for nutrient acquisition are shown in Figure 4. SusX and 
MalE are cellsurface lipoprotein components of ATP-binding cassette transport 
systems. Bacterial cell-wall-linked proteins involved in binding to eukaryotic cell 
surface carbohydrate residues are PulA and BgaA. PulA is a pullulanase mainly studied 
in group A Streptococcus. BgaA is a β-galactosidase studied in S. pneumoniae. 
 
 
Figure 4 Summary of mechanisms by which carbohydrate utilization proteins 
contribute to pathogenesis in S. pneumoniae and group A Streptococcus.26 
For several types of bacterial infections, such as Streptococcus pneumoniae, 
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Neisseria meningitides, Haemophilus influenzae, and Salmonella typhi, 
glycoconjugate vaccines can be based on fragments of capsular polysaccharides. 
Various oligosaccharide-conjugate vaccines based on the capsular or O-specific 
polysaccharides exhibit good immunogenic properties. The synthesis of clearly 
defined molecular entities will render possible the study of the influences of these 
parameters as well as of the characterization of the effects of different carrier 
molecules. 
Anti-cancer vaccines are intended to treat cancers (therapeutic vaccines) or to 
delay or preferably prevent a relapse of cancer (prophylactic vaccines) after any other 
form of (radical) therapy. Cancer cell antigens may be unique to individual tumors, 
shared by several tumor types, or expressed by the normal tissue from which the 
tumor grows. Some of these antigens are carbohydrates and several trials are being 
carried out to explore their possibilities to be used for the development of vaccines. 
For example, on breast cancer cells Mucin-1 (MUC-1), NER-2/neu, carcino- 
embryonic antigen (CEA), Sialyl Tn (STn) and Globo H have been found. The 
MUC-1 STn epitope: Neu5Aca2-6GalNAca1-O conjugated to KLH (Biomira Inc. 
Edmonton, Alta., Canada), given in combination with the adjuvant DETOX-B is 
currently under investigation.27, 28 
Since the large-scale synthesis of carbohydrates is no longer a limiting factor, the 
preparation of carbohydrate-based and structurally well-defined vaccines has become 
feasible.29 We now screening for the optimal length of the carbohydrate chain and the 
most suitable spacer and most effective (protein). The vaccines based on the 
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carbohydrates will lead to wide clinical applications.  
2.4 Aminoglycoside in antibiotics 
Aminoglycoside antibiotics (Figure 5) are the drug of choice in the anti-infective 
armamentarium. Despite the potential for renal toxicity, ototoxicity, and bacterial 
resistance, several members of this class of antibiotics have enjoyed several decades of 
clinical use.30 Unfortunately, years of continuous use and misuse have also caused the 
bacteria to acquire different types of resistance which has seriously compromised the 
clinical usage of aminoglycosides. 
The aminoglycosides are active against both Gram-positive and Gram-negative 
bacteria. They exert their antibacterial activities by first entering the cell irreversibly 
through active transportation and then binding to the particular regions or sites of RNA 
molecules in the bacterial ribosome, thus effectively interfering with the fidelity of 
mRNA translation. This interference of the translation process results in malformed 
proteins. A few of these miscoded proteins become part of the cell wall causing the 
disruption of the integrity of bacterial membrane.31,32 The damaged membrane 
subsequently allows more antibiotic molecules to enter the cell. Structurally related 
aminoglycosides bind to this region of rRNA and interfere with the protein synthesis by 
inducing codon misreading (Figure 6). 
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Figure 5. Structures of aminoglycosides 
 
 
 
 
 
 
 
 
Figure 6. Ribosomal protein synthesis and the 16S rRNA site for aminoglycoside 
binding33 
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3. Click reaction and 1,2,3-triazole in antibiotic 
1,2,3-triazole is one of a pair of isomeric chemical compounds with molecular 
formula C2H3N3, which have a five-membered ring of two carbon atoms and three 
nitrogen atoms, a basic aromatic heterocycle, which can be used in research as a 
building block for more complex chemical compounds, such as pharmaceutical drugs 
like tazobactam.34 1,2,3-Triazole and substituted 1,2,3-triazoles can be produced using 
the Azide Alkyne Huisgen Cycloaddition35 (Figure 7) in which an azide and an alkyne 
undergo a 1,3-dipolar cycloaddition reaction. But under the heat condition, the reaction 
always gives a mixture of 1,2,3-triazole and 1,2,4-triazole which means the 
regioselectivity is poor. 
Several members of the 1,2,3-triazole family have indeed shown interesting 
biological properties, such as anti-allergic,36 anti-bacterial,37 and anti-HIV activity.38 
Additionally, 1,2,3-triazoles are found in herbicides, fungicides, and dyes. 
 
Figure 7. Azide Alkyne Huisgen Cycloaddition 
In 2001, K. Barry Sharpless’s group introduced “click chemistry” as a new 
chemical methodology which could generate substances quickly and reliably by joining 
small units together. “Click Chemistry” refers to a 1,3-cyclo-addition of azides with 
terminal acetylenes using a Cu+ catalyst (Figure 8) at room temperature discovered 
concurrently and independently by the groups of K. Barry Sharpless and Morten 
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Meldal.  
OPh
N
N+N Ph- CuSO4-5H2O, 1 mol%sodium ascorbate, 5 mol%
H2O/tBuOH, 2:1, RT, 8h
N
N
N
PhO
Ph
 
Figure 8. Click reaction catalyzed by Cu catalyst 
The cyclozation reactions of Sharpless’s research gave a very good yield and 
regioselectivity under very mild reaction conditions. The catalyst was Cu(I), which was 
formed by Cu(II) salt and the reductive reagent sodium ascorbate. “Cick chemistry” has 
emerged as a fast and efficient approach to synthesize novel compounds with desired 
function by using selected “near perfect” reactions. 
  
Figure 9. Proposed mechanism for click reaction by Sharpless 
In 2002, the mechanism of this kind click reaction was first proposed (Figure 9). 
The reaction began with formation of copper (I) acetylide I, then the concerted [2+3] 
cycloaddition (B-directed) and pointed to a stepwise, annealing sequence 
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(B-1_B-2_B-3, hence the term “ligation”, which proceeded via the intriguing 
sixmembered copper-containing intermediate III. In 2007, Bernd F. Straub’s group 
isolated a Cu(I) triazolide, the click intermediate.39 They developed a straightforward 
synthesis to Cu(I) phenyl acetylide complexes with a saturated NHC (N-heterocyclic 
carbene-based) ligand (Scheme 1). The NHC Cu(I) halide complexes have recently 
been reported as highly active catalysts for triazole click reaction.40 
 
Scheme 1. Preparation of a copper(I) triazolide complex 
In carbohydrate chemistry, many methods were available in the current literature to 
prepare homo and hetero dimers of oligosaccharides and glycoconjugates. Some of the 
important methods that gave access to these interesting compounds were (i) olefin 
metathesis of alkenyl glycosides;41 (ii) intermolecular enyne metathesis of alkynyl and 
alkenyl glycosides;42 (iii) native chemical ligation of oligosaccharides to peptides;43 (iv) 
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glycosylation of diols;44 (v) the cycloaddition of azide and alkyne under modified 
Huisgen (“click”) conditions;45 and (vi) coupling of alkynyl glycosides.46 Since click 
reactions were found, they have been quickly applied in the protocol of carbohydrate 
substrates. Regarding the biological significance of the products, continued interests (in 
the application of click chemistry to carbohydrate substrates) prompted us to develope 
an efficient procedure, which was for the conjugation of oligosaccharides to 
oligosaccharides/amino acids. For instance, in 2008, a carbohydrate sensing “click- 
fluor” was reported which displayed a nontypical binding preference with sample 
saccharides. A fluorescent sensor was generated as a result of click reaction which 
formed a triazole ring (Figure 10).47 
 
Figure 10. Modular fluorescent saccharide sensors based on a 1,2,3-triazole ring 
Most of our group’s works were based on carbohydrate chemistry such as 
modifications on different carbohydrate derivatives, in order to improve the antibiotic 
activities. For example, the trehalose was modified, which was very important in 
antitubercular drug development. Recently in our approach, 1,2,3-triazole ring was 
introduced via click reaction between different saccharide part and other bioactive 
moieties like cholesterol. Some synthetic modifications were carried out by utilizing 
the click reaction between azido sugar and cholesterol alkyne moiety to get 
  
18
sugar-cholesterol conjugant containing 1,2,3-triazole ring. Some new techniques were 
used to assist our synthetic procedure, such as sonication. In recent years, the 
application of sonication in synthetic methodologies has gained considerable interest 
as it can enhance the rate, yield and selectivity of such reactions.48 It can also 
facilitate reactions at ambient conditions eliminating requirement of drastic conditions 
such as temperature, pressure and concentration. 
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CHAPTER 2 
DESIGN AND SYNTHESIS OF TREHALOSE BASED INHIBITORS AND 
ANTIBIOTICS 
1. Rationale for the design of trehalose 
Tuberculosis (TB) is still the leading cause of death from a single infectious 
agent.49, 50 Once curable, M. tuberculosis (MDR-TB) has shown multi-drug-resistant 
variants which challenged normal therapeutic practices and increased mortality rates 
worldwide.51 The high lipophilicity of the bacterial cell wall of Mycobacterium, 
which lowers the permeability of antitubercular agents and contributes to significant 
drug resistance, imposes great challenges in developing new drugs against TB. 
Recent advances in the studies of the lipid envelope of TB have uncovered a 
unique structural component, 6,6’-dimycolyltrehalose (TDM), which forms the 
outmost layer of the bacterial cell wall of TB (Figure 11).  
 
 
 
 
 
 
 
 
Figure 11. The lipid cell wall of Mycobacterium tuberculosis and the TDM 
structure 
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Three homologous proteins (AG 85 A, B, C), which possess mycolyltransferase 
activity, are responsible for the biosynthesis of TDM. Damage to the cell wall, due to 
the inhibition of ag 85, has been shown to increase the efficacy of various antibiotics. 
Also, the biosynthesis pathways of trehalose have been discovered (Figure 12). So we 
designed some trehalose derivatives to imitate the trehalose and those derivatives 
would inhibit the biosynthesis pathway of trehalose (Figrue 13). In our group’s 
previous work,52 an analog molecule containing a trehalose core with mono- or 
di-subistituted hydrocarbon side chain had been synthesized. As the linkages for 
attaching these hydrocarbon chains, amide and urea linkages were introduced (Figure 
14), which were commonly found in the designs of inhibitors against proteases, 
esterases, and peptidases.  
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Figure 12. Biosynthesis pathways of trehalose 
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Figure 13. Potential inhibitors for trehalose biosynthesis pathway 
 
Figure 14. Structures of the second generation inhibitors. 
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After completion of the synthesis, the trehalose derivatives were assayed against 
M. smegmatis (ATCC 14468), using isoniazid (INH) as the positive control. Some 
synthesized compounds showed positive result in this test (Table 4). Especially for 
compound YH23 and YH37, they almost had the same result as INH (Figure 15). 
Table 4. Inhibition zones of trehalose derivatives against M. smegmatis 
Compound Inhibition 
zone 
(mm) 
Compound Inhibition 
zone 
(mm) 
Compound Inhibition 
zone 
(mm) 
Compound Inhibition 
zone 
(mm) 
INH 
(Isoniazid) 
YH001 
 
YH002 
 
YH003 
 
YH004 
 
YH005 
 
YH006 
YH007 
18 
 
Inactive 
 
Inactive 
 
Inactive 
 
Inactive 
 
Inactive 
 
Inactive 
Inactive 
YH008 
 
YH011 
 
YH012 
 
YH014 
 
YH017 
 
YH018 
 
YH019 
YH020 
6 
 
Inactive 
 
10 
 
7 
 
6 
 
5 
 
5 
Inactive 
YH023 
 
YH024 
 
YH025 
 
YH026 
 
YH027 
 
YH028 
 
YH029 
YH030 
18 
 
5 
 
10 
 
8 
 
Inactive 
 
Inactive 
 
Inactive 
Inactive 
YH031 
 
YH032 
 
YH033 
 
YH034 
 
YH035 
 
YH036 
 
YH037 
YH041 
8 
 
11 
 
6 
 
Inactive 
 
Inactive 
 
12 
 
19 
 
Inactive 
 
Figure 15. Result of YH23 assayed against M. smegmatis 
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2. Synthesis of potential inhibitors 
Based on previous work, the potential inhibitors 6-azido-trehalose and 6,6’- 
diazido-trehalose (Figure 16) were chosen as the target compounds. 
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Figure 16. Inhibitors for trehalose biosynthetic OtsA-OtsB Pathway 
2.1   Synthesis of 6, 6’-diazido-trehalose 
Firstly, the trehalose was tosylated. The solubility of trehalose was very low in 
most organic solvents because of its polarity, so pyridine was used as the reaction 
solvent and DMAP as the catalyst. Then without further purification, the crude product 
was directly used to do azido substitution. TLC showed the reaction complete, but the 
product was too polar to be purified by column chromatography. In order to lower the 
polarity, acetylaction reaction was run. And then the mixture was purified by a gradient 
column chromatography. After hydrolysis, the target compound 6,6’-diazido-trehalose 
was obtained with a low yield (only 17%). 
In order to improve the yield, the procedure was modified by switching the order 
of acetylation and azido substitution. The modified route gave a much better result with 
64.7% yield in four steps (Scheme 2). 
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Scheme 2. Synthesis route of 6,6’-diazido-trehalose 
2.2 Synthesis of 6-azido-trehalose 
However, for another compound, 6-azido-trehalose, the synthesis was more 
difficult compared with 6,6’-diazido-trehalose. Treatment of trehalose with 1 equiv. 
TsCl in pyridine (Scheme 3) only gave di-substituted product instead of desired 
mono-substituted product. The reason for this result might be that the solubility of 
trehalose was not good in pyridine. Once it was tosylated, the reduced polarity made it 
more soluble than trehalose which meant the mono-substituted trehalose was more 
reactive. The mono-substituted one then continued to react with TsCl which made the 
final product disubstituted. 
TsCl(1eq), Pyr Ac2O, Pyr, DMAP
DMAP
O
OH
OHO
O
HO
HO
HO HO
OH
OH
O
OAc
OAcO
O
AcO
TsO
AcO AcO
OAc
OAc
 
Scheme 3. Route 1 for synthesis of monosubstituted trehalose 
Therefore the second route (Scheme 4) was tried. 2,4,6-Triisopropyl- 
benzenesulfonyl chloride was chosen because it was a more bulky leaving group, 
slowing down the substitution rate. The reaction was very slow and would not go 
without heating or sonication. 
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Scheme 4. Synthesis route of monosubstituted trehalose by TIBSCl 
The reaction worked when NaI was added and was assisted by sonicatiing for half 
hour. After acetylation and purification, the yield of desired monosubstituted 
compound was only 22%. To improve the yield, another modification was made 
(Scheme 5). First, the trehalose was brominated by using NBS and PPh3 in DMF, 
which created a mixture of mono- and di-substituted products. After acetylation and 
purification, the desired compound, the mono-substituted one, was obtained with 52% 
yield with two steps. Then after the azido substitution and hydrolysis reactions, 
6-azido-trehalose was obtained. 
3. Trehalose-based antitubercular agents 
Our group has synthesized a library of antitubercular compounds, which were 
based on trehalose core. In order to do further research work on this project, another 
molecule was designed to prepare (Figure 17), which was very similar to YH23 and 
YH37. 
Trehalose reacted with TrCl in DMF to form compound 11. The reaction was 
catalyzed by triethylamine. Then compound 11 reacted with BnBr and NaH in DMF, 
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catalyzed by TBAI. After the deprotection for -Tr groups, compound 13 was obtained 
(Scheme 6). These three steps had a total yield 40% and can be run in a big scale. 
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Scheme 5. Synthesis route of 6-azido-trehalose 
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Figure 17. New molecule for antitubercular assay 
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Scheme 6. Synthesis route of trehalose diol 
The side chain part was synthesized by n-heptylamine and BOC-glycine via peptide 
coupling condition (Scheme 7). The next step was to introduce a leaving group to the 
trehalose diol, then run the nuclephilic substitution by amine side chain. Several 
different methods were tried, but the results were not good (Scheme 8). 
C7H15NH2 + Boc-NHCH2COOH
EDC,HOBt
Et3N,DMF
BocNHCH2CONHC7H15
TFA,CH2Cl2 NH2CH2CONHC7H15
14
15  
Scheme 7. Synthesis route of compound 15. 
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Scheme 8. Synthesis approaches for compound 10 
So, slight modification was carried on this trehalose based molecule (Figure 18). 
An amino acid moiety was the first choice to be introduced between trehalose and 
aliphatic chain to form two amides. Amino acids were chosen because of their 
biological activity, and because they are abundant and easily available. So, a new 
library of trehalose analogues would be synthesized by using different commercial 
amino acids. The synthetic route for this molecule is shown as Scheme 9.  
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Figure 18. Modified trehalose analogue molecules with amino acid moiety (in red).  
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Scheme 9. Synthesis route of compound 19 
Primarily, the trehalose diol was treated by tosylation followed by azido 
substitution. The azido compound was reduced by Staudinger reaction into amine. This 
amine coupled with BOC-glycine. The BOC group was removed by trifluoro acetic 
acid. Then another peptide coupling reaction with heptanoic acid was run. After 
hydrogenation, the desired compound was obtained. 
However, the solubility of this product in water was low. If a chemical was able to 
be applied in drug, it was required to have some solubility in water. Otherwise it was 
hard to be absorbed by human being. So in order to improve this kind compound’s 
solubility, compound 25 was designed (Figure 19). Amine was introduced to replace 
amide as the fuctional groups which could increase the hydophilicity.  
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Figure 19. Structure of Compound 25 
Based on this idea, the first approach was to directly reduce the amide by LiAlH4, 
under reflux (Scheme 10). Even in a high boiling point solvent (pyridine) and long 
reaction time (2 days), TLC result showed there was no reaction, which meant the 
amide was hard to be reduced in this condition. The reason might be a large steric 
hindrance resulting from the long side chain which made the reduction reaction 
difficult to occur. Then an effort was made to reduce the amide after deprotection of 
BOC group (Scheme 11). There was still no reaction. 
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Scheme 10. Approach 1 for compound 25 
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Scheme 11. Approach 2 for amide reduction 
It seemed that the direct reduction of amide connected at 6 and 6’ positions would 
not work. An alternative approach was tried. After nucleophilic substitution, a 
reaction was run to reduce the amide which was connected to the side chain instead of 
trehalose. The result showed that this substitution reaction still did not work (Scheme 
12). 
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Scheme 12. Approach 3 for compound 26 
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The fourth approach was reductive amination. Swern oxidation was used to convert 
alcohol into aldehyde. The aldehyde reacted with primary amine and reductive reagent, 
generally NaBH3CN. During the reaction, the aldehyde was reduced and coupled with 
the amine on the carbon in carbonyl group at the same time. A model reaction was run. 
A reductive amination reaction was utilized to reduce the dialdehyde which was formed 
by oxidation of trehalose diol. The reaction worked well (Scheme 13).  
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Scheme 13. Model reaction for reductive amination 
Then another amine was tried, N-hexylethylenediamine, to run the same reduction 
(Scheme 14). The reductive reaction happened since the aldehyde disappeared on TLC 
plate. After purification, some aldehyde was reduced into diol, but it was difficult to 
afford our desired compound.  
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Scheme 14. Approach 4 for compound 25 
  
33
Conclusion 
For this project, two trehalose based inhibitors (6,6’-diazido-trehalose and 
6-azido-trehalose) have been successfully synthesized. The reaction conditions have 
been optimized. The best route for 6-azido-trehalose’s synthesis was bromination of 
trehalose with NBS followed by acetylation (see Scheme 5). Then the mono- 
brominated trehalose was separated with an acceptable yield. This route could be used 
in synthesis of other mono-substituted trehalose analogues. And a new trehalose 
analogue was designed and synthesized for antitubercular assay. Comparing with other 
core trehalose reagents, these analogues contained different amino acid units between 
trehalose and the side aliphatic chain. These analogues could serve as the leading 
compounds for further synthetic modification and pave the way to the development of a 
new generation of antibiotic. We are currently working on increasing the water 
solubility of this analogue. Further work is required for the modification on the 
aliphatic chain. 
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CHAPTER 3 
DESIGN AND SYNTHESIS OF CHOLESTEROL DERIVATIVES 
1. Background 
Steroid is a terpenoid lipid characterized by a carbon skeleton with four fused rings, 
generally arranged in a 6-6-6-5 fashion. Steroids vary by the functional groups attached 
to these rings and the oxidation state of the rings. Hundreds of distinct steroids are 
found in plants, animals, and fungi. All steroids are made in cells either from the sterol 
lanosterol (Figure 20) (animals and fungi) or the sterol cycloartenol (plants). Both 
sterols are derived from the cyclization of the triterpene squalene. 
 
 
 
Figure 20. Steroid skeleton of lanosterol and its synthesis pathway 
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It is possible to classify steroids based upon their chemical composition. Table 5 
shows examples. 
Table 5 Classification of steroids 
Class Examples 
Number of 
carbon 
atoms 
Structure 
 
 
Cholstanes 
 
Cholanes 
 
Pregnanes 
 
Androstanes 
 
Estranes 
 
cholesterol 
 
cholic acid 
 
progesterone 
 
testosterone 
 
estradiol 
 
27 
 
22 
 
21 
 
19 
 
18 
 
 
 
 
Many steroids have bioactivities, such as anabolic-androgenic steroids (AAS), a 
class of steroid hormones which are related to the hormone testosterone. AAS increase 
protein synthesis within cells, resulting in the buildup of cellular tissue (anabolism), 
especially in muscles. Anabolic steroids also have androgenic and virilizing properties, 
including the development and maintenance of masculine characteristics such as the 
growth of the vocal cords and body hair.  
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Cholesterol is a lipid found in the cell membranes of all animal tissues, and it is 
transported in the blood plasma of all animals. Cholesterol is also a sterol (a 
combination steroid and alcohol). Because cholesterol is synthesized by all eukaryotes, 
trace amounts of cholesterol are also found in membranes of plants and fungi. Most of 
the cholesterol in the body is synthesized by the body and some has dietary origin. 
Cholesterol is more abundant in tissues which either synthesize more or have more 
abundant densely-packed membranes, for example, the liver, spinal cord and brain. It 
plays a central role in many biochemical processes, such as the composition of cell 
membranes and the synthesis of steroid hormones.  
Cholesterol is required in the membrane of mammalian cells for normal cellular 
function, and is either synthesized in the endoplasmic reticulum, or derived from the 
diet, in which case it is delivered by the bloodstream in low-density lipoproteins. These 
are taken into the cell by LDL receptor-mediated endocytosis in clathrin-coated pits, 
and then hydrolyzed in lysosomes. Cholesterol is primarily synthesized from acetyl 
CoA through the HMG-CoA reductase pathway (Figure 21) in many cells and tissues. 
About 20–25% of total daily production (~1 g/day) occurs in the liver; other sites of 
higher synthesis rates include the intestines, adrenal glands, and reproductive organs.  
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Figure 21. HMG-CoA reductase pathway 
Recently, steroid derivatives have been studied in antibiotic assays such as 
antiinflammatory and antitumor.53-55 Many of them have high efficacy and low toxicity. 
These compounds can be isolated from natural source or synthesized in lab. For 
example, new cationic steroid antibiotics (CSA) were developed to imitate the 
antibacterial behavior of some endogenous peptide antibiotics.56 This behavior includes 
selective association of the antibiotics with and disruption of bacterial membranes.57, 58 
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This activity results in rapid bactericidal activity with a minimal potential for causing 
the emergence of resistance. 
These antibiotics, in general, adopt cationic, facially amphiphilic conformations 
(Figure 22), which appears to be the key requirement for antibacterial activity, and 
membrane selectivity is primarily derived from ionic recognition of negatively charged 
bacterial membranes. 
 
Figure 22. Structure of CSA (1) and a schematic representation of a CSA-peptide 
conjugate (2). 
 
It is reported that some steroidal oligoglycosides isolated from the Antarctic starfish 
Acodontaster conspicuous have very good antimicrobial abilities. Those compounds 
are dominated by glycosides composed of steroidal aglycons having the hydroxyl 
groups typically disposed on one side of the tetracyclic nucleus, i.e., 3β, 4β, 6α, 8, 15β-, 
with some having a sulfate at C-6, and differing in the side chains and/or in the 
disaccharide moieties that are usually attached at C-26, with some at C-28 and C-29 
(Figure 23). 
 
 
  
39
 
 
. 
Figure 23. The steroid oligoglycosides isolated from the Antarctic starfish 
Acodontaster conspicuous 
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2. Design and synthesis 
Our project was based on cholesterol in which the sugar moiety was introduced by 
using click reaction and formed a 1,2,3-triazole ring (Figure 24). First, the azido sugar 
part was synthesized as Scheme 15. 
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Figure 24. Target compound of steroid-carbohydrate conjugates 
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Scheme 15. Synthesis route of azido sugar moieties 
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In the synthesis of those sugar moieties, the general method was applied in most of 
sugars except for two aminosugars, glucosamine and galactosamine. Those two sugars 
were hard to get their chlorine or bromine substituted intermediates, which made it 
impossible to run azido substitution. So another route was used to synthesize those two 
azido sugars. Sugar was put in dry acetic chloride and kept stirring for 2 days. Then the 
reaction afforded 1-chloride sugar and some peracetylated products. 
The cholesterol part was synthesized by using cholesterol to react with propargyl 
bromide. Then it reacted with azido sugar via click reaction forming 1,2,3-triazole ring 
as expected. (Scheme 16).  
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Scheme 16. Synthesis route of cholesterol sugar conjugated compound 
After a series of this kind of compounds was synthesized, some antibiotic tests were 
applied to them such as against Mycobacterium smegmatis. Unfortunately those 
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compounds did not show any obvious bioactivity. 
Conclusion 
In summary, we have synthesized a new class of cholesterol derivative compounds, 
in which carbohydrate moiety and cholesterol were linked together by click reaction. 
1,2,3-Triazole was introduced in this kind of compounds. The reaction conditions for 
the synthesis route have been optimized. Although there is no obvious bioactivity found 
in antibiotic tests, it is still possible to apply this method in other similar projects. 
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CHAPTER 4 
EXPERIMENTAL SECTION AND DATA 
Proton magnetic resonance spectra were recorded using a Jeol 300 MHz or Bruker 
400 MHz spectrometers. Chemical shifts were reported as parts per million (ppm) 
downfield from tetramethylsilane in unit, and coupling constants were given in cycles 
per second (Hz). Splitting patterns were designed as s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet. 13C spectra were obtained using the Jeol 270 spectrometer at 68 
MHz or Bruker 400 spectrometers at 100 MHz. Routine 13C NMR spectra were fully 
decoupled by broad-band waltz decoupling. All NMR spectra were recorded at ambient 
temperature unless otherwise noted. Low-resolution fast-atom bombardment (LRFAB) 
and High-resolution fast-atom bombardment (HRFAB) or High-resolution MALDI 
were provided by the Mass Spectrometry Facilities, University of California, Riverside. 
Chemical reagents and starting materials were purchased from Aldrich Chemical 
Co. or Acros Chemical Co. and were used without purification unless otherwise noted. 
Dichloromethane was distilled over CaH2. Other solvents were used without 
purification. 
6, 6’-Diazido-α-D-trehalose (1) 
2.4 equiv. TsCl (6.7 g, 35.1 mmol) and DMAP (0.02 g) were added to a solution 
containing 5 g trehalose (14.6 mmol) in pyridine (50 mL). The reaction was stirred for 
12 hours. After the completion of the reaction, the crude product was directly used for 
the next step. 9 equiv. Ac2O (6.2mL, 0.13 mol) was added to the reaction solution. The 
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reaction was stirred for 4-5 hours and monitored by TLC. Then it was quenched with 
saturated NaHCO3 (aq, 10 mL) and diluted by ethyl acetate (30 mL). The organic 
solution was washed twice by saturated NaHCO3 (aq, 20 mL), brine (20 mL) and H2O 
(20 mL), respectively. The organic layer was collected and dried by anhydrious Na2SO4 
(10 g). After removal of the organic solvent, the crude product was dissolved in DMF 
(40 mL). 4 equiv. NaN3 (2 g) was added. The reaction was stirred for 12 hours under 
80oC. Then it was cooled down to room temperature. After removal of most of DMF, 
the solution was diluted by ethyl acetate (50 mL). The organic solution was washed 
twice by saturated NaHCO3 (aq, 20 mL), brine (20 mL) and H2O (20 mL), respectively. 
The organic layer was collected and dried by anhydrous Na2SO4. After removal of the 
solvent, the mixture was purified with a gradient column chromatography 
(hexanes:EtOAc = 100:0 to 50:50), the product was obtained as clear oil (4.3 g, 65%). 
Then 1 g product was dissolved in methanol and 2 drops MeOH/NaOMe solution was 
added as catalyst. The reaction was monitored by TLC. Two hours later it was 
quenched by H+ resin (2 g) and filtered through celite. After removal of the solvent; 
compound 1 was obtained as clear oil. (0.5 g, 100%). (1). 1H NMR (CD3OD, 400 MHz): 
δ 5.12 (d, J = 3.7 Hz, 1H), 4.03 (m, 1H), 3.75 (t, J = 9.4 Hz, 1H), 3.52 (t, J = 3.9 Hz, 2H), 
3.49 (d, J = 3.2 Hz, 2H), 3.40 (dd, J1 = 13.2 Hz, J2 = 3.8 Hz, 2H), 3.31 (m, 2H). 13C 
NMR (CD3OD, 100 MHz): δ 94.4 (2C), 73.2 (2C), 71.9 (2C), 71.8 (2C), 71.4 (2C), 51.4 
(2C). 
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6-O-2,4,6-triisopropylbenzeneesulfonyl-2,2’,3,3’,4,4’,6’-hepta-acetyl- 
α-D-trehalose (3): 
Trehalose (0.3 g, 0.88 mmol), TIBSCl (0.32 g, 2.2 mmol) and 1.2 equiv. NaI (0.16 g, 
1.07 mmol) were dissolved in pyridine (20 mL). The reaction was sonicated for 20 min. 
After acetylation (refer to the acetylation in preparation of compound 1), the mixture 
was purified by a gradient column chromatography (hexane:EtOAc = 100:0 to 50:50), 
compound 3 was obtained as yellow oil (0.08 g, 22%). 1H NMR (CDCl3, 400 MHz): δ 
7.19 (s, 2H), 5.50, (m, 2H), 5.25 (d, J = 3.8 Hz, 1H), 5.24 (d, J = 2.5 Hz, 1H), 5.10 (dd, 
J1 = 10.3 Hz, J2 = 3.8 Hz, 1H), 5.06 (dd, J1 = 10.1, J2 = 9.4, 1H), 4.95 (m, 2H), 4.25 (m, 
1H), 4.22 (m, 1H), 4.15-3.95 (m, 6H), 2.90 (m, 1H), 2.12 (s, 3H), 2.09 (s, 3H), 2.07 (s, 
6H), 2.05 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.28 (s, 3H), 1.26 (s, 6H), 1.25 (s, 3H), 1.24 
(s, 3H), 1.23 (s, 3H). 
6,6’-Dibromo-2,2’,3,3’,4,4’-hexa-acetyl-α-D-trehalose (6) and 6-bromo-2,2’,3,3’, 
4,4’,6’-hepta-acetyl-α-D-trehalose (7) 
Trehalose (2 g, 5.8 mmol), NBS (2.6 g, 14.5 mmol) and PPh3 (3.8 g, 14.5 mmol) 
were dissolved in pyridine (50 mL). The reaction was stirred for 3 days. After 
acetylation (refer to the acetylation in preparation of compound 1) and removal of the 
solvent, the mixture was purified with a gradient column chromatography 
(hexane:EtOAc = 100:0 to 50:50), compound 6 (0.3 g, 22%) and compound 7 (2.6 g, 
44%) were obtained. 
6-Azido-α-D-trehalose (9) 
Compound 7 (0.5 g, 0.7 mmol) and 4 equiv. NaN3 (0.2 g, 2.8 mmol) were dissolved 
in DMF (10 mL). The reaction was stirred for 12 hours under 80oC. Then it was cooled 
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down to room temperature. After the removal of most DMF by compressed air, it was 
diluted by ethyl acetate and washed twice by saturated NaHCO3 (aq, 20 mL), brine (20 
mL) and H2O (20 mL), respectively. The organic layer was collected and dried by 
anhydrous Na2SO4 (5 g). After purification with a gradient column chromatography 
(hexane:EtOAc = 100:0 to 50:50), compound 8 was obtained as clear oil (0.33 g, 52%). 
Then 0.1 g compound 8 was dissolved in methanol (10 mL) and 2 drops 
MeOH/NaOMe solution were added as catalyst. After the reaction was stirred for 2 
hours, it was quenched by H+ resin and filtered through celite. Removal of the solvent 
afforded compound 9 as clear oil (0.05 g, 100%). 1H NMR (CD3OD, 400 MHz): δ 5.14 
(d, J = 3.7 Hz, 1H), 5.12 (d, J = 3.7 Hz, 1H), 4.02 (m, 1H), 3.85 (m, 1H), 3.79 (m, 3H), 
3.67 (m, 1H), 3.5 (m, 3H), 3.39 (dd, J1 = 13.2 Hz, J2 = 5.8 Hz, 1H), 3.32 (m, 2H). 13C 
NMR (CD3OD, 100 MHz): δ 94.5 (1C), 94.0 (1C), 73.5 (1C), 73.2 (1C), 72.7 (1C), 72.0 
(1C), 71.6 (1C), 71.4 (1C), 70.8 (1C), 61.5 (1C), 60.3 (1C), 51.5 (1C). 
2,2’,3,3’,4,4’-Hexa-benzyl-α-D-trehalose (13) 
Trehalose (10 g, 0.03 mol), TrCl (20 g, 0.072 mol) and Et3N (12 mL, 0.072 mL) 
were dissolved in DMF (40 mL). The reaction was stirred for 12 hours. Then it was 
quenched by 2 mL MeOH. After removal of most of DMF, the crude product of 
compound 11, BnBr (32 mL, 0.27 mol), 9 equiv. NaH (10.6 g, 0.27 mol) and TBAI (0.1 
g, catalyst) were dissolved in anhydrous THF (60 mL). The reaction was stirred for 12 
hours. Then it was quenched by 5 mL MeOH. The reaction solution was poured into a 
beaker containing 300 g ice. The mixture was stirred for half an hour and diluted by 200 
mL ethyl acetate. The organic solution was washed twice by saturated NaHCO3 (aq, 20 
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mL), brine (20 mL) and H2O (20 mL) respectively. The organic layer was collected and 
dried by anhydrous Na2SO4 (20 g). After removal of the solvent, it afforded the crude 
product 12. The crude compound 12 and 3 equiv. TsOH (17 g) were dissolved in 
CH2Cl2 (250 mL) and MeOH (50 mL). The reaction was stirred for 12 hours. Then it 
was quenched by saturated NaHCO3 (aq, 20 mL). The solution was washed twice by 
saturated NaHCO3 (aq, 20 mL), brine (20 mL) and H2O (20 mL), respectively. The 
organic layer was collected and dried by anhydrous Na2SO4 (20 g). After removal of the 
solvent, the mixture was purified with a gradient column chromatography 
(hexanes/EtOAc 100:0 to 50:50). Compound 13 was obtained as yellow oil (32 g, 
68%). 
Aminoacetic heptylamide (15) 
BOC-glycine (0.76 g, 4.3 mmol), n-heptyl amine (0.64 mL, 4.3 mmol), 1.5 equiv. 
EDC (1.25 g, 6.5 mmol), 1.5 equiv. HOBt (0.88 g, 6.5 mmol) and 2 equiv. Et3N (1.22 
mL, 8.6 mmol) were dissolved in DMF (20 mL). The reaction was stirred for 2 days. 
After removal of the solvent, crude compound 14 was obtained. Compound 14 and 
TFA (3 mL) were dissolved in CH2Cl2 (25 mL). One hour later, after removal of the 
solvent, crude compound 15 was obtained as yellow oil. 
6,6’-Di-p-toluenesulfonyl-2,2’,3,3’,4,4’-hexa-benzyl-α-D-trehalose (16) 
Compound 13 (0.6 g, 0.68 mmol), TsCl (0.54 g, 2.7 mmol), Et3N (0.48 mL, 0.68 
mmol) and DMAP (0.1 g) were dissolved in CH2Cl2 (10 mL). The reaction was stirred 
for 12 hours. After removal of the solvent, crude compound 16 was obtained.  
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6,6’-Ditrifluoromethanesulfonyl-2,2’,3,3’,4,4’-hexa-benzyl-α-D-trehalose (17) 
Compound 13 (0.1 g, 0.11 mmol), Tf2O (0.1 mL, 0.3 mmol) and pyridine (0.48 g, 
0.35 mmol) were dissolved in CH2Cl2 (10 mL) under 0oC. The reaction was stirred for 
half hour. After removal of the solvent, crude compound 17 was obtained. 
6,6’-Dimethanesulfonyl-2,2’,3,3’,4,4’-hexa-benzyl-α-D-trehalose (18) 
Compound 13 (0.1 g, 0.11 mmol), MsCl (0.1 mL, 0.44 mmol) and Et3N (0.148 mL, 
0.11 mmol) were dissolved in CH2Cl2 (10 mL).  The reaction was stirred for half hour. 
Then the solution was washed by brine (10 mL). The organic layer was collected and 
dried by anhydrous Na2SO4 (2 g). After removal of the solvent, crude compound 18 was 
obtained. 
6,6’-Dideoxy-6,6’-di(monohexanoylaminoacetyl)amino-α-D-trehalose (19) 
The crude compound 16 (from 4.6 g compound 13 as the procedure above) and 4 
equiv. NaN3 (3.3 g, 20.8 mmol) were dissolved in DMF (50 mL). The reaction was 
stirred for 12 hours under 80oC. After the reaction was complete, most DMF was 
removed by compressed air. The solution was diluted by EtOAc (50 mL) and washed it 
twice by saturated NaHCO3 (aq, 20 mL), brine (20 mL) and H2O (20 mL), respectively. 
The organic layer was collected and dried by anhydrous Na2SO4 (10 g). After removal 
of the solvent followed by purification with a gradient column chromatography 
(hexane:EtOAc = 100:0 to 75:25), it afforded compound 20 as yellow oil (4.11 g, 89%). 
Compound 20 (0.46 g, 0.49 mmol) was dissolved with PMe3 (0.12 mL, 1.18 mmol) in 
THF (5 mL), One drop water was added. The reaction was heated to 50 oC. After 2.5 
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hours it was cooled down to room temperature. After removal of the solvent, it was 
purified by a gradient column chromatography (hexane:EtOAc = 100:0 to 25:75), 
which afforded compound 21 as yellow oil (0.31 g, 81%). Compound 21 (0.31g, 0.35 
mmol), BOC-glycine solid (0.15 g, 0.84 mmol), EDC (0.1 g, 0.53 mmol), HOBt (0.07 g, 
0.53 mmol) and Et3N (0.2 mL, 0.7 mmol) were dissolved in DMF (10 mL). The 
reaction was stirred for 12 hours.. After removal of most DMF, the solution was diluted 
by EtOAc (20 mL) and washed twice by saturated NaHCO3 (aq, 20 mL), brine (20 mL) 
and H2O (20 mL), respectively. The organic layer was collected and dried by anhydrous 
Na2SO4 (5 g). After removal of the solvent, the mixture was purified by a gradient 
column chromatography (hexane:EtOAc = 100:0 to 25:75), compound 22 was obtained 
as yellow oil (0.27 g, 79%). 1H NMR (CDCl3, 400 MHz): δ 7.37-7.26 (m, 15H), 5.95, (s, 
1H), 5.10 (d, J = 3.4 Hz, 1H), 5.02-4.61 (m, 6H), 4.1 (m, 2H), 3.78 (m, 1H), 3.64 (d, J = 
4.0 Hz, 2H), 3.52 (dd, J1 = 9.7 Hz, J2 = 3.5 Hz, 1H), 3.32 (t, J = 9.3 Hz, 1H), 3.06 (m, 
1H), 1.44 (s, 9H). 13C NMR (CDCl3, 100 MHz): δ 169.5 (1C), 138.8 (1C), 138.2 (1C), 
138.1 (1C), 128.7-127.5 (15C), 94.0 (1C), 81.8 (1C), 80.4 (1C), 79.6 (1C), 78.5 (1C), 
75.8 (1C), 75.5 (1C), 73.3 (1C), 69.7 (1C), 44.5 (1C), 39.4 (1C), 28.5 (3C). 
The BOC groups of compound 22 were deprotected as the procedure in preparation 
of compound 15. Compound 23 was obtained. Without further purification, it was 
directly used to run peptide coupling reaction with heptoic acid following the same 
procedure for compound 22. After purification with a gradient column chromatography 
(hexane:EtOAc = 100:0 to 25:75), compound 24 was obtained as yellow oil (0.14 g, 
68%). 1H NMR (CDCl3, 400 MHz): δ 7.41-7.23 (m, 15H), 6.77, (s, 1H), 6.42 (s, 1H), 
  
50
5.10 (d, J = 3.4 Hz, 1H), 4.99-4.59 (m, 6H), 4.08 (m, 2H), 3.82 (d, J = 4.9 Hz, 2H), 3.63 
(m, 1H), 3.53 (dd, J1 = 9.6 Hz, J2 = 3.4 Hz, 1H), 3.31 (t, J = 9.3 Hz, 1H), 3.20 (m, 1H), 
2.19 (t, J = 7.4 Hz, 2H), 1.56 (m, 2H), 1.24 (m, 6H), 0.87 (t, J = 6.6 Hz, 3H). 
Compound 24 (0.14 g, 0.12 mmol) was dissolved in degassed MeOH (5 mL). Pd/C 
(0.1 g, 10%) was added as catalyst. The reaction was stirred for 12 hours under N2 
atmosphere. The reaction mixture was filtered through celite-silica gel. After removal 
of the solvent, compound 19 was obtained as white crystal (0.06 g, 93%). 1H NMR 
(CD3OD, 400 MHz): δ 5.05 (d, J = 2.9 Hz, 1H), 3.90 (t, J = 6.8 Hz, 1H), 3.85 (s, 2H), 
3.76 (t, J = 9.2 Hz, 1H), 3.62 (d, J = 13.2 Hz, 1H), 3.53 (dd, J1 = 9.4 Hz, J2 = 2.8 Hz, 1H), 
3.35 (m, 2H), 3.16 (t, J = 9.2 Hz, 1H), 2.80 (m, 2H), 2.28 (t, J = 7.1 Hz, 2H), 1.96 (m, 
2H), 1.63 (m, 2H), 1.33 (m, 6H), 0.91 (t, J = 6.0 Hz, 3H). 13C NMR (CD3OD, 100 
MHz) : δ 175.8 (1C), 170.9 (1C), 94.7 (1C), 72.9 (1C), 72.1 (1C), 72.0 (1C), 70.9 (1C), 
42.5 (1C), 40.3 (1C), 35.7 (1C), 31.5 (1C), 28.9 (1C), 25.6 (1C), 22.4 (1C), 13.2 (1C). 
Appoaches for 6,6’-Dideoxy-6,6’-di(monohexaminoethylene)amino-α-D-trehalose 
(25) 
Compound 24 (0.06g) and LiAlH4 (0.3 g) were dissolved in anhydrous THF (10 
mL). The reaction was refluxed for 12 hours. The solution was cooled down to room 
temperature. The reaction was quenched by pouring the solution into ice-water. 
Compound 23 was prepared from 0.12 g compound 22. The crude compound 23 
was dissolved in anhydrous THF (10 mL) with LiAlH4 (0.3 g). The reaction was 
refluxed for 2 days. 
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6,6’-Dideoxy-6,6’-di(monoheptyl)amino-α-D-trehalose (28) 
Dry CH2Cl2 was cooled by acetone-dry ice to -78 oC. (COCl) 2 (0.18 mL, 1 mmol) 
and DMSO (0.22 mL, 1.5 mmol) were added. Then compound 13 (0.22 g, 0.25 mmol) 
and Et3N (0.6 mL, 1 mmol) were added at -50oC. The reaction was under N2 
atmosphere. Two hous later, the solution was washed by HCl (3 M, 10 mL) three times 
and diluted by CH2Cl2 (20 mL). The organic layer was dried by anhydrous Na2SO4 (5 
g). After removal of the solvent, it afforded crude product compound 27. Crude 
compound 27, heptyl amine (0.19 mL, 0.55 mmol), 3 equiv. NaCNBH3 (0.06 g, 0.75 
mmol) and 10 drops acetic acid were dissolved in MeOH (10 mL). The reaction was 
stirred for 12 hours. It was quenched by saturated NaHCO3 (aq, 5 mL). The solution 
was extracted by CH2Cl2 (20 mL). After removal of the solvent, the mixture was 
purified with a gradient column chromatography (hexane:EtOAc = 100:0 to 35:65), it 
afforded compound 28 as yellow oil (0.11 g, 51%). 
2,3,4,6-O-tetraacetyl-1-azido-α-D-glucofuranose (47) 
Glucose (1.0 g, 5.6 mmol) and 8 equiv. Et3N (12 mL, 44 mmol) were dissolved in 
Ac2O (25 mL). The reaction was cooled to 0oC by ice. Two hours later, the reaction 
mixture was diluted by ethyl acetate (40 mL) and washed twice by saturated NaHCO3 
(aq, 20 mL), brine (20 mL) and H2O (20 mL), respectively. The organic layer was 
collected and dried by anhydrous Na2SO4 (5 g). After removal of the solvent, the crude 
compound 29 was obtained. Compound 29 (0.5 g, 0.74 mmol) and HBr (33% in HOAc, 
3 mL).were dissolved in CH2Cl2 (10 mL). Two hours later, the solution was diluted by 
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ethyl acetate (20 mL) and washed twice by saturated NaHCO3 (aq, 20 mL), brine (20 
mL) and H2O (20 mL) respectively. After removal of the solvent, the crude compound 
38 was obtained. The crude compound 38 and NaN3 (0.15 g, 1.5 mmol) were dissolved 
in DMF (20 mL). The reaction was stirred under 80 oC for 12 hours. Then most of DMF 
was removed by compressed air. The solution was diluted by ethyl acetate (20 mL) and 
washed twice by saturated NaHCO3 (aq, 20 mL), brine (20 mL) and H2O (20 mL), 
respectively. The organic layer was collected and dried by anhydrous Na2SO4 (5 g). 
After removal the solvent, the mixture was purified with a gradient column 
chromatography (hexane:EtOAc = 100:0 to 35:65), compound 47 was obtained as 
white crystal (0.4g, 82%). 
Synthesis of compound 48-55: 
Refer the procedure for synthesis of compound 47. 
2-Acetamido1-azido-3,4,6-triacetyl-α-D-glucopyranose (56) 
N-acetate glucosamine (2.0 g, 4.6 mmol) was dissolved in dry AcCl (20 mL). The 
reaction was stirred for 2 days. After the reaction was complete, it was quenched by 
pouring the solution into ice/water mixture. The reaction solution was extracted by 
ethyl acetate (3 × 15 mL). The organic layer was collected and dried by anhydrous 
Na2SO4. After removal of the solvent, the mixture was dissolved in CH2Cl2 (40 mL). 
Saturated NaHCO3 (aq, 20 mL), NaN3 (1 g, 18 mmol) and phase transfer catalyst 
n-Bu4NHSO4 (1.2 g) were added. The reaction was stirred for 24 hours. The organic 
layer was collected and washed twice by saturated NaHCO3 (aq, 20 mL), brine (20 mL) 
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and H2O (20 mL), respectively. The organic layer was collected and dried by anhydrous 
Na2SO4 (5 g). After removal of the solvent, the mixture was purified with a gradient 
column chromatography (hexane:EtOAc = 100:0 to 25:75), compound 56 was obtained 
as white crystal (1.6 g, 40%).  
2-Acetamido1-azido-3,4,6-triacetyl-α-D-galactopyranose (57) 
Refer the procedure for synthesis of compound 56. 
O-propargyl-cholesterol (58) 
Cholesterol (2.0 g, 5.17 mmol), NaH (0.3 g, 15.5 mmol), propargyl bromide (1.7 
mL, 15.5 mmol) and catalyst TBAI (0.1 g) were dissolved in anhydrous THF (50 mL). 
The reaction was sonicated for 35 min. After the reaction was complete.the solution 
was diluted by CH2Cl2 (39 mL) and filtered through celite. After purification with a 
gradient column chromatography (hexane:EtOAc = 100:0 to 0:100), compound 58 was 
obtained as a white crystal (1.6g, 77%). 
1-(2,3,4,6-Tetraacetyl-D-glucosyl)-4-cholesteryl-1,2,3-triazole (59) 
Compound 58 (0.05 g, 0.12 mmol), 1 equiv. compound 47 (0.05 g, 0.12 mmol), 
Cu(OAc)2 (0.01 g) and Na-ascorbate (0.02 g) were dissolved in a mixed solvent 
(MeOH:THF:H2O = 4 mL:1.1 mL:0.7 mL). The reaction was sonicated for 28 min. 
Then the solution was filtered through celite. After removal of the solvent, the mixture 
was purified with a gradient column chromatography (hexane:EtOAc = 100:0 to 50:50), 
compound 59 was obtained as yellow oil (0.06 g, 73%). 1H NMR  (CDCl3, 400 MHz): 
δ 7.78 (s, 1H), 5.89 (d, J = 9.0 Hz, 1H), 5.37 (m, 2H), 5.23(m, 1H), 5.13 (m, 1H), 4.67 (s, 
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2H), 4.27 (dd, J1 = 12.7 Hz, J2 = 5.1 Hz, 1H), 4.18 (dd, J1 = 14.6 Hz, J2 = 2.3 Hz, 1H), 
4.00 (m, 1H), 3.30(m, 1H), 2.40 (m, 1H), 2.25 (m, 1H), 2.09 (s, 3H), 2.07 (s, 3H), 
2.15-1.78 (m, 5H), 2.04 (s, 3H), 1.88 (s, 3H), 1.60-1.14 (m, 23H), 1.01 (s, 3H), 0.91 (d, 
J = 6.5 Hz, 3H), 0.85 (dd, J1 = 6.6 Hz, J2 = 1.7 Hz, 6H), 0.7 (s, 3H). 13C NMR (CDCl3, 
100 MHz): δ 170.7 (1C), 170.1 (1C), 169.6 (1C), 169.1 (1C), 147.1 (1C), 140.9 (1C), 
122.0 (1C), 120.9 (1C), 85.9 (1C), 79.3 (1C), 75.3 (1C), 73.0 (1C), 70.4 (1C), 67.9 (1C), 
61.8 (1C), 61.6 (1C), 57.0 (1C), 56.3 (1C), 50.4 (1C), 42.5 (1C), 40.0 (1C), 39.7 (1C), 
39.2 (1C), 37.4 (1C), 37.0 (1C), 36.4 (1C), 36.0 (1C), 32.2 (1C), 32.1 (1C), 32.0 (1C), 
29.9 (1C), 28.4 (1C), 28.2 (1C), 24.5 (1C), 24.0 (1C), 23.0 (1C), 22.8 (1C), 21.3 (1C), 
20.9 (1C), 20.7 (1C), 20.4 (1C), 19.6 (1C), 18.9 (1C), 12.1 (1C). 
Synthesis of compound 60-69: 
Refer the procedure for synthesis of compound 59. 
60. 1H NMR (CDCl3, 300 MHz): δ 7.83 (s, 1H), 5.84 (d, J = 9.3 Hz, 1H), 5.55 (m, 
2H), 5.35 (d, J = 5.7 Hz, 1H), 5.22 (dd, J1 = 9.6 Hz, J2 = 3.5 Hz, 1H), 4.67 (s, 2H), 4.12 
(m, 2H), 3.29 (m, 1H), 2.40 (m, 1H), 2.25 (m, 1H), 2.20 (s, 3H), 2.05-1.78 (m, 5H), 2.03 
(s, 3H), 2.0 (s, 3H), 1.89 (s, 3H)1.60-1.14 (m, 23H), 1.01 (s, 3H), 0.96 (d, J = 6.5 Hz, 
3H), 0.86 (d, J = 6.5 Hz, 6H), 0.7 (s, 3H). 13C NMR (CDCl3, 100 MHz) : δ 170.6 (1C), 
170.2 (1C), 170.0 (1C), 169.3 (1C), 146.9 (1C), 140.9 (1C), 122.0 (1C), 121.0 (1C), 
86.4 (1C), 79.2 (1C), 74.2 (1C), 71.1 (1C), 68.0 (1C), 67.1 (1C), 61.7 (1C), 61.4 (1C), 
57.0 (1C), 56.4 (1C), 50.4 (1C), 42.5 (1C), 39.9 (1C), 39.7 (1C), 39.2 (1C), 37.4 (1C), 
37.1 (1C), 36.4 (1C), 36.0 (1C), 32.2 (1C), 32.1 (1C), 28.4 (1C), 28.2 (1C), 24.5 (1C), 
24.0 (1C), 23.0 (1C), 22.8 (1C), 20.9 (1C), 20.7 (1C), 20.5 (1C), 19.6 (1C), 18.9 (1C), 
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12.1 (1C). 
61. 1H NMR (CDCl3, 400 MHz): δ 7.83 (s, 1H), 5.79 (d, J = 9.3 Hz, 1H), 5.55 (t, J = 
10.0 Hz, 1H), 5.38 (dd, J1 = 13.3 Hz, J2 = 2.8 Hz, 1H), 5.23 (dd, J1 = 10.2 Hz, J2 = 3.3 Hz, 
1H), 4.67 (q, J1 = 14.7 Hz, J2 = 12.4 Hz, 2H), 4.12 (m, 1H), 3.29(m, 1H), 2.40 (m, 1H), 
2.25 (s, 3H), 2.00 (s, 3H), 2.15-1.78 (m, 5H), 1.89 (s, 3H), 1.60-1.14 (m, 23H), 1.26 (d, 
J = 6.4 Hz, 3H), 1.01 (s, 3H), 0.92 (d, J = 6.5 Hz, 3H), 0.86 (dd, J1 = 6.6 Hz, J2 = 1.8 Hz, 
6H), 0.7 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 170.6 (1C), 170.1 (1C), 169.4 (1C), 
146.8 (1C), 140.9 (1C), 122.0 (1C), 120.9 (1C), 86.5 (1C), 78.9 (1C), 72.8 (1C), 71.5 
(1C), 70.1 (1C), 68.1 (1C),61.6 (1C), 57.0 (1C), 56.3 (1C), 50.4 (1C), 42.5 (1C), 40.0 
(1C), 39.7 (1C), 39.1 (1C), 37.4 (1C), 37.1 (1C), 36.4 (1C), 36.0 (1C), 35.8 (1C), 32.2 
(1C), 32.1 (1C), 28.5 (1C), 28.4 (1C), 28.2 (1C), 24.9 (1C), 24.5 (1C), 24.0 (1C), 23.0 
(1C), 22.8 (1C), 21.3 (1C), 20.9 (1C), 20.8 (1C), 20.5 (1C), 19.6 (1C), 18.9 (1C), 16.3 
(1C), 12.1 (1C). 
62. 1H NMR (CDCl3, 300 MHz): δ 7.79 (s, 1H), 6.09 (s, 1H), 5.70 (s, 1H), 5.35(d, J 
= 5.7 Hz, 1H), 5.22 (m, 2H), 4.67 (s, 2H), 3.80 (m, 1H), 3.29 (m, 1H), 2.40 (m, 1H), 
2.25 (m, 1H), 2.10 (s, 3H), 2.15-1.78 (m, 5H), 1.98 (s, 3H), 1.57 (s, 3H), 1.35 (d, J = 5.9 
Hz, 3H), 1.60-1.14 (m, 23H), 1.01 (s, 3H), 0.96 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.5 Hz, 
6H), 0.7 (s, 3H).  
63. 1H NMR (CDCl3, 300 MHz): δ 7.76 (s, 1H), 6.11 (s, 1H), 5.71 (d, J = 2.0 Hz, 
1H), 5.32(m, 3H), 4.67 (s, 2H), 4.30 (dd, J1 = 12.4 Hz, J2 = 6.2 Hz, 1H), 4.20 (dd, J1 = 
12.0 Hz, J2 = 2.1 Hz, 1H), 3.94 (m, 1H), 3.28 (m, 1H), 2.40 (m, 1H), 2.25 (m, 1H), 2.09 
(s, 3H), 2.08 (s, 3H), 2.15-1.78 (m, 5H), 1.99 (s, 3H), 1.55 (s, 3H), 1.60-1.14 (m, 23H), 
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0.99 (s, 3H), 0.88 (d, J = 6.5 Hz, 3H), 0.85 (dd, J1 = 6.8 Hz, J2 = 1.0 Hz, 6H), 0.7 (s, 3H). 
13C NMR (CDCl3, 100 MHz) : δ 170.8 (1C), 170.0 (1C), 169.8 (1C), 169.2 (1C), 146.9 
(1C), 140.7 (1C), 122.1 (1C), 121.5 (1C), 84.9 (1C), 79.1 (1C), 75.9 (1C), 71.0 (1C), 
69.0 (1C), 65.1 (1C), 62.5 (1C), 61.7 (1C), 57.0 (1C), 56.3 (1C), 50.4 (1C), 42.5 (1C), 
39.9 (1C), 39.7 (1C), 39.2 (1C), 37.3 (1C), 37.1 (1C), 36.4 (1C), 36.0 (1C), 32.2 (1C), 
32.1 (1C), 28.4 (1C), 28.2 (1C), 24.5 (1C), 24.0 (1C), 23.0 (1C), 22.8 (1C), 21.2 (1C), 
20.9 (1C), 20.8 (1C), 20.7 (1C), 19.6 (1C), 18.9 (1C), 12.1 (1C). 
64. 1H NMR (CDCl3, 400 MHz): δ 7.74 (s, 1H), 5.79 (d, J = 9.0 Hz, 1H), 5.40 (m, 
3H), 5.20 (m, 1H), 4.67 (s, 2H), 4.30 (dd, J1 = 11.7 Hz, J2 = 5.7 Hz, 1H), 3.59 (t, J = 
10.5 Hz, 1H), 3.27(m, 1H), 2.38 (m, 1H), 2.25 (m, 1H), 2.09 (s, 3H), 2.06 (s, 3H), 
2.15-1.78 (m, 5H), 1.89 (s, 3H), 1.60-1.14 (m, 23H), 1.01 (s, 3H), 0.91 (d, J = 6.5 Hz, 
3H), 0.86 (dd, J1 = 6.6 Hz, J2 = 1.7 Hz, 6H), 0.7 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 
170.1 (1C), 170.0 (1C), 169.2 (1C), 140.9 (1C), 127.1 (1C), 122.0 (1C), 117.3 (1C), 
86.5 (1C), 79.1 (1C), 72.3 (1C), 70.6 (1C), 68.6 (1C), 65.8 (1C), 61.6 (1C), 57.0 (1C), 
56.3 (1C), 50.4 (1C), 42.5 (1C), 40.0 (1C), 39.7 (1C), 39.2 (1C), 37.4 (1C), 37.0 (1C), 
36.4 (1C), 36.0 (1C), 32.1 (1C), 32.0 (1C), 29.9 (1C), 28.4 (2C), 28.2 (1C), 24.5 (1C), 
24.0 (1C), 23.0 (1C), 22.8 (1C), 21.3 (1C), 20.9 (1C),20.4 (1C), 19.6 (1C), 18.9 (1C), 
12.1 (1C). 
65. 1H NMR (CDCl3, 400 MHz): δ 7.71 (s, 1H), 5.83 (d, J = 9.0 Hz, 1H), 5.46-5.35 
(m, 3H), 5.17 (t, J = 9.3 Hz, 1H), 5.09 (t, J = 9.7 Hz, 1H), 4.97 (dd, J1 = 9.1 Hz, J2 = 8.0 
Hz, 1H), 4.68 (q, J1 = 14.0 Hz, J2 = 12.5 Hz, 2H), 4.55 (d, J = 7.9 Hz, 1H), 4.51 (dd, J1 
= 12.3 Hz, J2 = 1.5 Hz, 1H), 4.39 (dd, J1 = 12.6 Hz, J2 = 4.4 Hz, 1H), 4.15 (dd, J1 = 12.3 
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Hz, J2 = 5.0 Hz, 1H), 4.08 (dd, J1 = 12.5 Hz, J2 = 2.2 Hz, 1H), 3.91 (m, 2H), 3.69 (m, 
1H), 3.30(m, 1H), 2.39 (m, 1H), 2.25 (m, 1H), 2.12 (s, 3H), 2.11 (s, 3H), 2.052 (s, 3H), 
2.051 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H), 1.87 (s, 3H), 1.60-1.14 (m, 33H), 1.04 (s, 3H), 
0.91 (d, J = 6.4 Hz, 3H), 0.86 (dd, J1 = 6.6 Hz, J2 = 1.8 Hz, 6H), 0.7 (s, 3H). 13C NMR 
(CDCl3, 100 MHz): δ 170.7 (1C), 170.5 (1C), 170.4 (1C), 169.7 (1C), 169.5 (1C), 169.3 
(1C), 169.2 (1C), 146.9 (1C), 140.8 (1C), 122.1 (1C), 120.9 (1C), 101.1 (1C), 85.7 (1C), 
79.3 (1C), 76.1 (1C), 73.0 (1C), 72.6 (1C), 72.3 (1C), 71.8 (1C), 70.5 (1C), 67.9 (1C), 
61.9 (1C), 61.7 (1C), 56.9 (1C), 56.3 (1C), 50.4 (1C), 42.5 (1C), 39.9 (1C), 39.7 (1C), 
39.2 (1C), 37.3 (1C), 37.0 (1C), 36.4 (1C), 36.0 (1C), 32.1 (1C), 32.0 (1C), 28.4 (1C), 
28.2 (1C), 24.5 (1C), 24.0 (1C), 23.0 (1C), 22.8 (1C),21.3 (1C), 21.0 (1C), 20.9 (1C), 
20.8 (1C), 20.7 (1C), 20.5 (1C), 19.6 (1C),18.9 (1C), 12.0 (1C). 
66. 1H NMR (CDCl3, 400 MHz): δ 7.71 (s, 1H), 5.90 (d, J = 9.1 Hz, 1H), 5.49-5.27 
(m, 10H), 5.09 (t, J = 9.9 Hz, 1H), 4.78 (dd, J1 = 10.5 Hz, J2 = 4.0 Hz, 1H), 4.79 (dd, J1 
= 10.3 Hz, J2 = 4.0 Hz, 1H), 4.68 (t, J = 12.9 Hz, 2H), 4.48 (m, 3H), 4.34-4.18 (m, 3H), 
4.11-4.08 (m, 2H), 4.03-3.94 (m, 6H) , 3.30(m, 1H), 2.39 (m, 1H), 2.25 (m, 1H), 2.17 (s, 
3H), 2.16 (s, 3H), 2.11 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.023 (s, 3H), 
2.02 (s, 3H), 2.01 (s, 3H), 1.85 (s, 3H), 1.60-1.14 (m, 33H), 1.01 (s, 3H), 0.89 (d, J = 4.3 
Hz, 3H), 0.86 (dd, J1 = 6.6 Hz, J2 = 1.7 Hz, 6H), 0.7 (s, 3H). 13C NMR (CDCl3, 100 
MHz): δ 170.9 (1C), 170.8 (1C), 170.7 (1C), 170.6 (1C), 170.5 (1C), 170.2 (1C), 170.1 
(1C), 169.9 (1C), 169.7 (1C), 169.5 (1C), 146.9 (1C), 140.8 (1C), 122.1 (1C), 120.9 
(1C), 96.3 (1C), 95.9 (1C), 87.6 (1C), 85.4 (1C), 79.3 (1C), 75.4 (1C), 75.3 (1C), 73.7 
(1C), 72.7 (1C), 71.8 (1C), 71.1 (1C), 70.6 (1C), 70.3 (1C), 69.6 (1C), 69.4 (1C), 68.7 
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(1C), 68.1 (1C), 62.9 (1C), 62.4 (1C), 61.7 (1C), 61.6 (1C), 56.9 (1C), 56.3 (1C), 50.4 
(1C), 42.5 (1C), 39.9 (1C), 39.7 (1C), 39.1 (1C), 37.3 (1C), 37.0 (1C), 36.4 (1C), 35.9 
(1C), 32.1 (1C), 32.0 (1C), 29.9 (1C), 28.4 (1C), 28.2 (1C), 24.5 (1C), 24.0 (1C), 23.0 
(1C), 22.8 (1C),21.3 (1C), 21.0 (1C), 20.9 (1C), 20.85 (1C), 20.83 (1C), 20.7 (1C), 20.4 
(1C), 19.6 (1C),18.9 (1C), 12.0 (1C). 
67. 1H NMR (CDCl3, 400 MHz): δ 7.70 (s, 1H), 5.79 (d, J = 8.9 Hz, 1H), 5.46-5.33 
(m, 4H), 5.12 (dd, J1 = 10.4 Hz, J2 = 7.9 Hz, 1H), 4.96 (dd, J1 = 10.4 Hz, J2 = 3.4 Hz, 1H), 
4.67 (t, J = 12.9 Hz, 2H), 4.51 (d, J = 7.9 Hz, 1H), 4.45 (dd, J1 = 12.4 Hz, J2 = 1.5 Hz, 
1H), 4.11 (m, 4H), 3.93 (m, 3H), 3.28(m, 1H), 2.40 (m, 1H), 2.23 (m, 1H), 2.15 (s, 3H), 
2.09 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 1.96 (s, 3H), 1.85 (s, 3H), 1.60-1.14 
(m, 23H), 1.01 (s, 3H), 0.89 (d, J = 4.3 Hz, 3H), 0.86 (dd, J1 = 6.6 Hz, J2 = 1.7 Hz, 6H), 
0.7 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 170.6 (1C), 170.4 (1C), 170.3 (1C), 170.2 
(1C), 169.7 (1C), 169.4 (1C), 169.3 (1C), 146.9 (1C), 140.8 (1C), 122.1 (1C), 120.9 
(1C), 101.3 (1C), 85.6 (1C), 79.3 (1C), 76.0 (1C), 75.9 (1C), 72.9 (1C), 71.1 (1C), 71.0 
(1C), 70.6 (1C), 69.2 (1C), 66.8 (1C), 62.0 (1C), 61.7 (1C), 61.0 (1C), 56.9 (1C), 56.3 
(1C), 50.4 (1C), 42.5 (1C), 39.9 (1C), 39.7 (1C), 39.2 (1C), 37.3 (1C), 37.0 (1C), 36.4 
(1C), 35.9 (1C), 32.1 (1C), 32.0 (1C), 29.9 (1C), 28.4 (1C), 28.2 (1C), 24.5 (1C), 24.0 
(1C), 23.0 (1C), 22.8 (1C),21.3 (1C), 21.0 (1C), 20.9 (1C), 20.85 (1C), 20.83 (1C), 20.7 
(1C), 20.4 (1C), 19.6 (1C),18.9 (1C), 12.0 (1C). 
68. 1H NMR (CDCl3, 400 MHz): δ 7.83 (s, 1H), 6.00 (d, J = 9.9 Hz, 1H), 5.62 (d, J 
= 9.2 Hz, 1H ), 5.45 (t, J = 9.4 Hz, 1H), 5.37 (m, 1H), 5.24 (t, J = 9.83 Hz, 1H), 4.65 (s, 
2H), 4.55 (m, 1H), 4.28 (dd, J1 = 12.6 Hz, J2 = 5.1 Hz, 1H), 4.14 (dd, J1 = 12.7 Hz, J2 = 
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2.0 Hz, 1H), 3.97 (m, 1H), 3.32 (m, 1H), 2.42 (m, 1H), 2.28 (m, 1H), 2.09 (s, 3H), 2.08 
(s, 3H), 2.07(s, 3H), 1.78 (s, 3H), 2.05-1.82 (m, 8H), 1.58-1.06 (m, 17H), 1.04 (s, 3H), 
0.91 (d, J = 6.4 Hz, 4H), 0.86 (dd, J1 = 6.6 Hz, J2 = 1.8 Hz, 6H), 0.7 (s, 3H). 13C NMR 
(CDCl3, 100 MHz): δ 170.7 (1C), 170.5 (1C), 170.4 (1C), 169.5 (1C), 140.8 (1C), 122.1 
(1C), 120.9 (1C), 85.7 (1C), 79.3 (1C), 75.2 (1C), 72.4 (1C), 68.0(1C), 61.9 (1C), 61.7 
(1C), 57.0 (1C), 56.3 (1C), 53.9 (1C), 50.4 (1C), 42.5 (1C), 39.9 (1C), 39.7 (1C), 39.2 
(1C), 37.4 (1C), 37.1 (1C), 36.4 (1C), 36.0 (1C), 32.2 (1C), 32.1 (1C), 29.9 (1C), 28.5 
(1C), 28.2 (1C), 24.5 (1C), 24.0 (1C), 23.2 (1C), 23.0 (1C), 22.8 (1C),21.3 (1C), 20.9 
(1C), 20.8 (1C), 19.6 (1C),18.9 (1C), 12.0 (1C). 
69. 1H NMR (CDCl3, 300 MHz): δ 7.83 (s, 1H), 6.00 (d, J = 9.9 Hz, 1H), 5.84 (d, J 
= 8.9 Hz, 1H ), 5.45 (t, J = 10.3 Hz, 1H), 5.35 (m, 1H), 5.22 (t, J = 9.6 Hz, 1H), 4.65 (s, 
2H), 4.55 (m, 1H), 4.28 (dd, J1 = 12.4 Hz, J2 = 4.8 Hz, 1H), 4.14 (d, J1 = 12.3 Hz, 1H), 
3.98 (m, 1H), 3.32 (m, 1H), 2.42 (m, 1H), 2.28 (m, 1H), 2.07 (s, 3H), 2.06 (s, 6H), 1.78 
(s, 3H), 2.05-1.82 (m, 8H), 1.58-1.06 (m, 17H), 1.04 (s, 3H), 0.91 (d, J = 6.4 Hz, 4H), 
0.86 (d, J1 = 6.6 Hz, 6H), 0.67 (s, 3H). 13C NMR (CDCl3, 100 MHz): δ 171.0 (1C), 
170.8 (1C), 170.6 (1C), 169.5 (1C), 140.9 (1C), 128.9 (1C), 127.1 (1C), 122.1 (1C), 
86.0 (1C), 79.3 (1C), 75.2 (1C), 72.5 (1C), 68.1(1C), 61.9 (1C), 61.5 (1C), 57.0 (1C), 
56.3 (1C), 53.9 (1C), 50.4 (1C), 42.5 (1C), 40.0 (1C), 39.7 (1C), 39.1 (1C), 37.4 (1C), 
37.1 (1C), 36.4 (1C), 36.0 (1C), 32.2 (1C), 32.1 (1C), 32.0 (1C), 29.9 (1C), 28.5 (1C), 
28.2 (1C), 24.5 (1C), 24.0 (1C), 23.2 (1C), 23.0 (1C), 22.8 (1C),21.3 (1C), 20.9 (1C), 
20.8 (1C), 19.6 (1C),18.9 (1C), 12.0 (1C). 
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1-D-glucosyl-4-cholesteryl-1,2,3-triazole (70): 
Compound 59 (0.06g, 0.08 mmol) was dissolved in MeOH (5 mL). Two drops 
NaOMe/MeOH solution.were added as catalyst. The reaction was stirred for 1 hour. 
Then it was quenched by H+ resin (1 g) and filtered through celite. After removal of the 
solvent, compound 70 was obtained as white solid (0.04 g, 99%). 1H NMR (CD3OD, 
300 MHz): δ 8.15 (s, 1H), 5.61 (d, J = 9.1 Hz, 1H), 5.37 (d, J = 5.2 Hz, 1H), 4.67 (s, 2H), 
4.34 (m, 1H), 4.28 (m, 1H), 3.89 (m, 1H), 3.69 (dd, J1 = 12.3 Hz, J2 = 5.4 Hz, 1H), 3.58 
(m, 1H), 3.54, (dd, J1 = 16.6 Hz, J2 = 9.3 Hz, 1H), 2.40 (m, 1H), 2.20 (m, 1H), 2.05-1.78 
(m, 5H), 1.60-1.14 (m, 23H), 1.01 (s, 3H), 0.96 (d, J = 6.5 Hz, 3H), 0.86 (dd, J1 = 6.5 Hz, 
6H), 0.73 (s, 3H). 13C NMR (CD3OD, 100 MHz): δ 145.4 (1C), 140.6 (1C), 123.0 (1C), 
121.7 (1C), 88.4 (1C), 79.9 (1C), 78.9 (1C), 77.3 (1C), 72.8 (1C), 69.7 (1C), 61.2 (1C), 
60.6 (1C), 57.0 (1C), 56.4 (1C), 50.5 (1C), 42.3 (1C), 40.0 (1C), 39.5 (1C), 38.8 (1C), 
37.2 (1C), 36.7 (1C), 36.2 (1C), 35.9 (1C),32.0 (1C), 31.9 (1C), 29.6 (1C), 28.1 (1C), 
28.0 (1C), 24.1 (1C), 23.7 (1C), 22.0 (1C), 21.7 (1C), 21.0 (1C), 18.6 (1C), 18.0 (1C), 
11.1 (1C). ESI/APCI Calcd for C36H59N3O6Na ([M+Na]+) m/e 652.4295; measured m/e 
652.4296. 
Synthesis of compound 71-80: 
Refer the procedure for synthesis of compound 70. 
71. 1H NMR (CD3OD, 300 MHz): δ 8.18 (s, 1H), 5.56 (d, J = 9.3 Hz, 1H), 5.35 (d, J 
= 5.7 Hz, 1H), 4.67 (s, 2H), 4.12 (t, J = 9.6 Hz, 1H), 3.96 (d, J = 3.1 Hz, 1H), 3.80 (q, J1 
= 11.7 Hz, J2 = 5.5 Hz, 1H), 3.73 (t, J = 5.5 Hz, 1H), 3,65 (dd, J1 = 9.6 Hz, J2 = 3.5 Hz, 
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1H), 2.40 (m, 1H), 2.20 (m, 1H), 2.05-1.78 (m, 5H), 1.60-1.14 (m, 23H), 1.01 (s, 3H), 
0.96 (d, J = 6.5 Hz, 3H), 0.86 (dd, J = 6.5 Hz, 6H), 0.7 (s, 3H). 13C NMR (CD3OD, 100 
MHz) : δ 145.6 (1C), 140.6 (1C), 122.4 (1C), 121.7 (1C), 89.0 (1C), 78.8 (1C), 74.1 
(1C), 70.3 (1C), 69.2 (1C), 61.2 (1C), 60.6 (1C), 60.0 (1C), 56.4 (1C), 50.5 (1C), 42.3 
(1C), 39.9 (1C), 39.5 (1C), 38.8 (1C), 37.2 (1C), 36.7 (1C), 36.2 (1C), 35.9 (1C), 32.0 
(1C), 31.8 (1C), 28.1 (1C), 27.9 (1C), 24.1 (1C), 23.7 (1C), 22.0 (1C), 21.7 (1C), 21.0 
(1C), 18.6 (1C), 18.0 (1C), 11.1 (1C). ESI/APCI Calcd for C36H59N3O6Na ([M+Na]+) 
m/e 652.4295; measured m/e 652.4298. 
72. 1H NMR (CD3OD, 300 MHz): δ 8.16 (s, 1H), 5.51 (d, J = 9.3 Hz, 1H), 5.35 (d, J 
= 5.2 Hz, 1H), 4.64 (s, 2H), 4.05 (t, 1H, J = 9.3 Hz), 3.93 (dd, J1 = 12.7, 6.5 Hz, 1H), 
3.73 (d, J = 3.5 Hz, 2H), 3.66 (dd, J1 = 9.6 Hz, J2 = 3.4 Hz,1H), 2.38 (m, 1H), 2.19 (m, 
1H), 1.96 (m, 2H), 2.01-1.86 (m, 6H), 1.60-1.35 (m, 10H), 1.28 (d, J = 6.2 Hz, 3H), 
1.22-1.05 (m, 5H), 1.01 (s, 3H), 0.92 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 5.8, 6H), 0.7 (s, 
3H). 13C NMR (CD3OD, 100 MHz) : δ 145.6 (1C), 140.6 (1C), 122.3 (1C), 121.7 (1C), 
89.0 (1C), 79.0 (1C), 74.3 (1C), 74.1 (1C), 71.8 (1C), 70.0 (1C), 60.7 (1C), 57.0 (1C), 
56.4 (1C), 50.5 (1C), 42.3 (1C), 39.9 (1C), 39.5 (1C), 38.8 (1C), 37.2 (1C), 36.7 (1C), 
36.2 (1C), 35.9 (1C), 32.0 (1C), 31.9 (1C), 28.1 (1C), 28.0 (1C), 24.1 (1C), 23.8 (1C), 
22.0 (1C), 21.8 (1C), 21.0 (1C), 18.6 (1C), 18.1 (1C), 15.6 (1C), 11.1 (1C). ESI/APCI 
Calcd for C36H59N3O6Na ([M+Na]+) m/e 652.4295; measured m/e 652.4305. 
73. 1H NMR (CD3OD, 300 MHz): δ 8.1 (s, 1H), 5.95 (s, 1H), 5.36 (d, J = 4.8 Hz, 
1H), 4.63 (s, 2H), 4.07 (d, J = 2.8 Hz, 1H), 3.65 (dd, J1 = 8.9 Hz, J2 = 3.1 Hz,1H), 
3.58-3.43 (m, 2H), 2.39 (m, 1H), 2.2 (m, 1H), 2.05-1.78 (m, 5H), 1.65-1.40 (m, 10H), 
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1.35 (d, J = 5.9 Hz, 3H), 1.27-1.04 (m, 6H), 1.01 (s, 3H), 0.92 (d, J = 6.6 Hz, 3H), 0.86 
(d, J = 6.5 Hz, 6H), 0.7 (s, 3H). 13C NMR (CD3OD, 100 MHz) : δ 145.6 (1C), 140.6 
(1C), 123.2 (1C), 121.5 (1C), 86.9 (1C), 78.9 (1C), 75.6 (1C), 73.4 (1C), 71.8 (1C), 
71.1 (1C), 60.5 (1C), 56.8 (1C), 56.2 (1C), 48.5 (1C), 42.2 (1C), 39.8 (1C), 39.4 (1C), 
38.7 (1C), 37.0 (1C), 36.6 (1C), 36.0 (1C), 35.8 (1C), 31.9 (1C), 31.7 (1C), 28.0 (1C), 
27.8 (1C), 24.0 (1C), 23.6 (1C), 21.9 (1C), 21.6 (1C), 20.8 (1C), 18.5 (1C), 17.9 (1C), 
16.7 (1C), 11.0 (1C). ESI/APCI Calcd for C42H69N3O11Na ([M+Na]+) m/e 814.4830; 
measured m/e 814.4834. 
74. 1H NMR (CD3OD, 400 MHz): δ 8.28 (s, 1H), 6.03 (d, J = 1.1 Hz, 1H), 5.37 (d, J 
= 5.1 Hz, 1H), 4.67 (s, 2H), 4.12 (s, 1H), 3.92 (dd, J1 = 12.2 Hz, J2 = 2.2 Hz,1H), 
3.80-3.70 (m, 2H), 3.54 (m, 1H),  2.39 (m, 1H), 2.2 (m, 1H), 2.05-1.78 (m, 5H), 
1.60-1.14 (m, 23H), 1.01 (s, 3H), 0.96 (d, J = 6.5 Hz, 3H), 0.86 (dd, J1 = 6.6 Hz, J2 = 1.4 
Hz, 6H), 0.7 (s, 3H). 13C NMR (CD3OD, 100 MHz) : δ 145.6 (1C), 140.6 (1C), 123.4 
(1C), 121.7 (1C), 87.3 (1C), 80.4 (1C), 79.0 (1C), 73.7 (1C), 71.1 (1C), 66.5 (1C), 61.4 
(1C), 60.5 (1C), 56.9 (1C), 56.4 (1C), 50.5 (1C), 42.3 (1C), 39.9 (1C), 39.5 (1C), 38.8 
(1C), 37.2 (1C), 36.7 (1C), 3620 (1C), 35.9 (1C), 32.0 (1C), 31.8 (1C), 28.1 (1C), 27.9 
(1C), 24.1 (1C), 23.7 (1C), 22.0 (1C), 21.7 (1C), 21.0 (1C), 18.6 (1C), 18.0 (1C), 11.1 
(1C). ESI/APCI Calcd for C36H59N3O5 (M)+ m/e 614.4488; measured m/e 614.4524. 
75. 1H NMR (CD3OD, 400 MHz): δ 8.13(s, 1H), 5.50 (d, J = 9.1 Hz, 1H), 5.38 (m, 
1H), 4.67 (s, 2H), 4.02 (dd, J1 = 11.3 Hz, J2 = 5.4 Hz, 1H), 3.92 (t, J1 = 9.0 Hz, 1H), 
3.78-3.67 (m, 2H), 3.52-3.45 (m, 3H), 2. 40 (m, 1H), 2.25 (m, 1H), 2.07-1.86 (m, 5H), 
1.67-0.87 (m, 22H), 1.01 (s, 3H), 0.91 (d, J = 6.5 Hz, 3H), 0.89 (dd, J1 = 6.6 Hz, J2 = 1.7 
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Hz, 6H), 0.73 (s, 3H). 13C NMR (CD3OD, 75 MHz): δ 145.4 (1C), 140.6 (1C), 122.9 
(1C), 121.7 (1C), 89.0 (1C), 79.0 (1C), 77.4 (1C), 72.7 (1C), 69.5 (1C), 68.6 (1C), 60.6 
(1C), 57.0 (1C), 56.4 (1C), 50.5 (1C), 42.3 (1C), 40.0 (1C), 39.5 (1C), 38.8 (1C), 37.2 
(1C), 36.7 (1C), 36.2 (1C), 35.9 (1C), 32.0 (1C), 31.9 (1C), 28.1 (2C), 28.0 (1C), 24.1 
(1C), 23.7 (1C), 22.0 (1C), 21.7 (1C), 21.0 (1C), 18.6 (1C), 18.0 (1C), 11.1 (1C). 
ESI/APCI Calcd for C36H59N3O5Na ([M+Na]+) m/e 636.4352; measured m/e 636.4352. 
76. 1H NMR (DMSO, 400 MHz): δ 8.21 (s, 1H), 5.57 (d, J = 9.3 Hz, 1H), 5.31 (m, 
1H), 4.99 (m, 1H), 4.79 (m, 1H), 4.53 (s, 2H), 4.30 (d, J = 7.9 Hz, 1H), 3.97-2.96 (m, 
11H), 2.35 (m, 1H), 2.07 (m, 1H), 1.96-0.96 (m, 32H), 1.04 (s, 3H), 0.86 (d, J = 6.4 Hz, 
3H), 0.82 (dd, J1 = 6.6 Hz, J2 = 1.8 Hz, 6H), 0.62 (s, 3H). 13C NMR (DMSO, 100 MHz): 
δ 145.2 (1C), 141.0 (1C), 123.6 (1C), 121.9 (1C), 103.7 (1C), 87.6 (1C), 79.9 (1C), 78.4 
(1C), 78.3 (1C), 77.4 (1C), 77.0 (1C), 75.8 (1C), 73.9 (1C), 72.4 (1C), 70.7 (1C), 70.3 
(1C), 61.6 (1C), 60.9 (1C), 60.5 (1C), 56.8 (1C), 56.2 (1C), 50.2 (1C), 42.5 (1C), 37.3 
(1C), 36.9 (1C), 36.3 (1C), 35.8 (1C), 32.1 (1C), 28.5 (1C), 28.4 (1C), 28.0 (1C), 26.7 
(1C), 24.5 (1C), 23.8 (1C), 23.7 (1C), 23.3 (1C), 23.0 (1C),21.2 (1C), 19.8 (1C), 19.7 
(1C), 19.2 (1C), 12.3 (1C). ESI/APCI Calcd for C35H57N3O5Na ([M+Na]+) m/e 
622.4196; measured m/e 622.4196. 
77. 1H NMR (CD3OD, 400 MHz): δ 8.2 (s, 1H), 5.64 (d,), 5.39 (m, 1H), 5.26 (d, J = 
3.7 Hz, 1H), 5.17 (m, 1H), 4.67 (s, 2H), 4.48 (m, 3H), 3.98-3.20 (m, 31H), 2.40 (m, 1H), 
2.22 (m, 1H), 2.07-1.83 (m, 6H), 1.63-1.01 (m, 27H), 1.03 (s, 3H), 0.93 (d, J = 6.4 Hz, 
3H), 0.86 (dd, J1 = 6.6 Hz, J2 = 1.3 Hz, 6H), 0.7 (s, 3H). 13C NMR (CD3OD, 100 MHz): 
δ 170.9 (1C), 170.8 (1C), 170.7 (1C), 170.6 (1C), 170.5 (1C), 170.2 (1C), 170.1 (1C), 
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169.9 (1C), 169.7 (1C), 169.5 (1C), 146.9 (1C), 140.8 (1C), 122.1 (1C), 120.9 (1C), 
96.3 (1C), 95.9 (1C), 87.6 (1C), 85.4 (1C), 79.3 (1C), 75.4 (1C), 75.3 (1C), 73.7 (1C), 
72.7 (1C), 71.8 (1C), 71.1 (1C), 70.6 (1C), 70.3 (1C), 69.6 (1C), 69.4 (1C), 68.7 (1C), 
68.1 (1C), 62.9 (1C), 62.4 (1C), 61.7 (1C), 61.6 (1C), 56.9 (1C), 56.3 (1C), 50.4 (1C), 
42.5 (1C), 39.9 (1C), 39.7 (1C), 39.1 (1C), 37.3 (1C), 37.0 (1C), 36.4 (1C), 35.9 (1C), 
32.1 (1C), 32.0 (1C), 29.9 (1C), 28.4 (1C), 28.2 (1C), 24.5 (1C), 24.0 (1C), 23.0 (1C), 
22.8 (1C),21.3 (1C), 21.0 (1C), 20.9 (1C), 20.85 (1C), 20.83 (1C), 20.7 (1C), 20.4 (1C), 
19.6 (1C),18.9 (1C), 12.0 (1C). 
78. 1H NMR (DMSO, 400 MHz): δ 8.25 (s, 1H), 5.60 (d, J = 9.3 Hz, 1H), 5.55 (d, J 
= 5.9 Hz, 1H), 5.33 (m, 1H), 5.12 (d, J = 4.2 Hz, 1H),4.89 (m, 1H), 4.82 (m, 1H), 4.68 
(m, 2H), 4.54 (m, 2H), 4.24 (d, J = 7.0 Hz, 1H), 3.87-3.74 (m, 2H), 3.62-3.24 (m, 5H), 
2.36 (m, 1H), 2.10 (m, 1H), 1.96-0.96 (m, 33H), 1.04 (s, 3H), 0.86 (d, J = 6.4 Hz, 4H), 
0.82 (dd, J1 = 6.6 Hz, J2 = 1.8 Hz, 6H), 0.62 (s, 3H). 13C NMR (DMSO, 75 MHz): δ 
145.1 (1C), 141.0 (1C), 123.5 (1C), 121.8 (1C), 104.3 (1C), 87.5 (1C), 80.3 (1C), 78.3 
(2C), 76.1 (1C), 75.7 (1C), 73.8 (1C), 72.3 (1C), 71.1 (1C), 70.2 (2C), 68.7 (1C), 61.0 
(1C), 60.9 (1C), 60.5 (1C), 56.7 (1C), 56.1 (1C), 50.1 (1C), 42.4 (1C), 37.2 (1C), 36.8 
(1C), 36.2 (1C), 35.7 (1C), 32.0 (2C), 28.5 (1C), 28.4 (1C), 27.9 (1C), 26.6 (1C), 24.4 
(1C), 23.7 (1C), 23.2 (1C), 22.9 (1C), 21.2 (1C), 19.6 (1C), 19.7 (1C), 19.1 (1C), 12.2 
(1C). 
79. 1H NMR (CD3OD, 400 MHz): δ 8.13(s, 1H), 5.80 (d, J = 9.8 Hz, 1H), 5.38 (m, 
1H), 4.63 (s, 2H), 4.22 (m, 1H), 3.91 (m, 1H), 3.78-3.67 (m, 2H), 3.61-3.24 (m, 3H), 2. 
40 (m, 1H), 2.25 (m, 1H), 2.07-1.86 (m, 6H), 1.67-0.87 (m, 24H), 1.01 (s, 3H), 0.91 (d, 
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J = 6.5 Hz, 3H), 0.89 (dd, J1 = 6.6 Hz, J2 = 1.7 Hz, 6H), 0.73 (s, 3H). 13C NMR (CD3OD, 
75 MHz): δ 145.1 (1C), 140.5 (1C), 122.4 (1C), 121.6 (1C), 86.9 (1C), 80.1 (1C), 78.8 
(1C), 74.5 (1C), 70.1 (1C), 61.1 (1C), 60.5 (1C), 56.9 (1C), 56.4 (1C), 55.5 (1C), 50.5 
(1C), 42.3 (1C), 39.9 (1C), 39.5 (1C), 38.8 (1C), 37.1 (1C), 36.7 (1C), 36.1 (1C), 35.9 
(1C), 32.0 (1C), 31.8 (1C), 29.5 (1C), 28.1 (1C), 28.0 (1C), 26.3 (1C), 24.1 (1C), 23.7 
(1C), 22.0 (1C), 21.7 (1C), 21.4 (1C), 21.0 (1C), 18.6 (1C), 18.1 (1C), 11.1 (1C). 
80. 1H NMR (CD3OD, 400 MHz): δ 8.13 (s, 1H), 5.80 (d, J = 9.8 Hz, 1H), 5.38 (m, 
1H), 4.63 (s, 2H), 4.22 (t, J = 10.0 Hz, 1H), 3.90 (m, 1H), 3,78-3.32 (m, 5H), 2.38 (m, 
1H), 2.21 (m, 1H), 2.07-1.11 (m, 28H), 0.96 (d, J = 6.5 Hz, 4H), 0.89 (dd, J1 = 6.6 Hz, 
J2 = 1.7 Hz, 6H), 0.73 (s, 3H). 13C NMR (CD3OD, 100 MHz): δ 143.1 (1C), 140.7 (1C), 
122.0 (1C), 121.7 (1C), 86.9 (1C), 80.2 (1C), 74.6 (1C), 70.5 (1C), 70.1 (1C), 61.1 (1C), 
57.1 (1C), 56.4 (1C), 55.5 (1C), 50.5 (1C), 42.8 (1C), 39.1 (1C), 38.8 (1C), 37.2 (1C), 
36.2 (1C), 35.9 (1C), 32.0 (1C), 31.9 (1C), 29.6 (1C), 28.1 (1C), 28.0 (1C), 26.4 (1C), 
23.7 (1C), 23.6 (1C), 22.0 (1C), 21.7 (1C), 21.4 (1C), 19.5 (1C), 18.6 (1C), 18.0 (1C), 
12.7 (1C), 11.1 (1C). ESI/APCI Calcd for C48H79N3O16Na ([M+Na]+) m/e 976.5358; 
measured m/e: (m/z) 976.5346. 
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                 Major: Organic Chemistry    Academic Degree: M.S. 
 
1996.9 — 2000.6   Department of Chemistry,                     Wuhan 
University 
                 Major: Organic Chemistry    Academic Degree: B.S. 
 
RESEARCH EXPERIENCE: 
1. Click Reaction in Carbohydrate Derivatives Synthesis: 
1-glycopyranosyloxylhexyl - 4- methylenethiol -1,2,3- triazoles carbohydrate chips 
synthesis. 
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2. Synthesis of some inhibitors and potential targets for the development of new 
antitubercular drugs based on the trehalose. 
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Inhibitors for Trehalose Biosynthetic OtsA-OtsB Pathway 
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3. Potential anticancer drugs: cholesterol derivatives 
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